[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1969
1. Lupu M, Sullivan EW, Westfall TE, Little MT, Weigler BJ, Moore PF, Stroup PA, Zellmer E, Kuhr C, Storb R: Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma. J Am Vet Med Assoc; 2006 Mar 1;228(5):728-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma.
  • Histologic examination and immunophenotyping of biopsy specimens confirmed a stage V (b) T-cell malignant lymphoma.
  • TREATMENT AND OUTCOME: Clinical remission was attained by use of 2 chemotherapy cycles, followed by an allogeneic hematopoietic cell transplant performed at 18 weeks after diagnosis.
  • Remission has been confirmed by normal results of serum thymidine kinase assays and the absence of peripheral blood clonal T-cell receptor gene rearrangements.
  • Outcome of allogeneic hematopoietic cell transplantation in dogs can be excellent because of improved donor-recipient selection by use of molecular dog leukocyte antigen typing, compared with early attempts, and better prevention of graft versus host disease, better supportive care, and substitution of peripheral blood mononuclear cells for bone marrow.
  • [MeSH-major] Dog Diseases / therapy. Hematopoietic Stem Cell Transplantation / veterinary. Histocompatibility Antigens / immunology. Immunosuppression / veterinary. Lymphoma, T-Cell / veterinary
  • [MeSH-minor] Animals. Cyclosporine / pharmacology. Dogs. Graft Survival. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cell Mobilization. Histocompatibility Testing. Male. Transplantation Chimera. Transplantation, Homologous / veterinary. Treatment Outcome. Whole-Body Irradiation / veterinary

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506937.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


2. Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF: A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother; 2010 Feb-Mar;33(2):178-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
  • We evaluated the efficacy and safety of patient-specific immunotherapy with mitumprotimut-T idiotype keyhole limpet hemocyanin and granulocyte-monocyte colony-stimulating factor (GM-CSF) following rituximab in patients with follicular B-cell lymphoma.
  • Patients with previously untreated or relapsed/refractory CD20+ follicular lymphoma received 4 weekly infusions of rituximab and those with a complete response (CR), partial response (PR), or stable disease received mitumprotimut-T and GM-CSF injections subcutaneously.
  • Among 103 patients treated with rituximab, 92 (54 relapsed/refractory and 38 previously untreated) received mitumprotimut-T/GM-CSF; median age was 53 years, 91% had stage III to IV disease, and 59% had failed earlier therapy.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Immunotherapy. Lymphoma, B-Cell / therapy. Lymphoma, Follicular / therapy. Recombinant Fusion Proteins / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145546.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Immunoglobulin Idiotypes; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin
  •  go-up   go-down


3. Al-Saleem T, Al-Mondhiry H: Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood; 2005 Mar 15;105(6):2274-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms.
  • IPSID is a variant of the B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), which involves mainly the proximal small intestine resulting in malabsorption, diarrhea, and abdominal pain.
  • IPSID lymphomas reveal excessive plasma cell differentiation and produce truncated alpha heavy chain proteins lacking the light chains as well as the first constant domain.
  • Early-stage IPSID responds to antibiotics (30%-70% complete remission).
  • Most untreated IPSID patients progress to lymphoplasmacytic and immunoblastic lymphoma invading the intestinal wall and mesenteric lymph nodes, and may metastasize to a distant organ.
  • IPSID lymphoma shares clinical, morphologic, and molecular features with MALT lymphoma, lymphoplasmacytic lymphoma, and plasma cell neoplasms.
  • [MeSH-major] Campylobacter Infections. Campylobacter jejuni. Immunoproliferative Small Intestinal Disease. Lymphoma, B-Cell, Marginal Zone. Plasma Cells / immunology
  • [MeSH-minor] Adolescent. Adult. Africa. B-Cell-Specific Activator Protein / genetics. B-Cell-Specific Activator Protein / immunology. Child. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 9 / genetics. Chromosomes, Human, Pair 9 / immunology. Female. Humans. Immunoglobulin Light Chains / genetics. Immunoglobulin Light Chains / immunology. Immunoglobulin Variable Region / genetics. Immunoglobulin Variable Region / immunology. Immunoglobulin alpha-Chains / genetics. Immunoglobulin alpha-Chains / immunology. Intestine, Small / immunology. Intestine, Small / pathology. Lymph Nodes / immunology. Lymph Nodes / pathology. Male. Mesentery / immunology. Mesentery / pathology. Middle East. Sequence Deletion / genetics. Sequence Deletion / immunology. Translocation, Genetic / genetics. Translocation, Genetic / immunology

  • MedlinePlus Health Information. consumer health - Campylobacter Infections.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for immunoproliferative small intestinal disease .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542584.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Variable Region; 0 / Immunoglobulin alpha-Chains; 0 / PAX5 protein, human
  • [Number-of-references] 78
  •  go-up   go-down


Advertisement
4. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol; 2009 Jul 10;27(20):3346-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
  • PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.
  • PATIENTS AND METHODS: Eighty-two patients (median age, 64 years; 79% stage III/IV, one to nine prior treatments) received four once-weekly doses of 80 to 750 mg/m(2) of veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity.
  • In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular Lymphoma International Prognostic Index > or = 2), and at all dose levels.
  • In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00285428/ NCT00596804
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab
  •  go-up   go-down


5. Stefanovic A, Morgensztern D, Fong T, Lossos IS: Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. Leuk Lymphoma; 2008 Jul;49(7):1311-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database.
  • Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT).
  • There is limited information on clinical presentation, natural history and treatment of this type of lymphoma.
  • We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our institution and patients from the surveillance epidemiology and end results (SEER) database.
  • Twenty-one patients (median age 57) with disease stage IE (n = 10) and IV (n = 11), were treated at our institution.
  • We identified 326 patients (59% females and 41% males; median age 68 [30 to 85) with BALT lymphoma in the SEER database.
  • Fifty-five per cent had stage IE, 10% stage IIE, 3% stage IIIE, and 22% stage IV disease.
  • [MeSH-major] Lung Neoplasms. Lymphoma, B-Cell, Marginal Zone

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604720.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Carotta S, Nutt SL: Losing B cell identity. Bioessays; 2008 Mar;30(3):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Losing B cell identity.
  • The transcription factor Pax5 is essential for the initial commitment of hematopoietic progenitors to the B cell lineage.
  • Recently, our understanding of the lineage commitment process has been extended with the finding that Pax5 is also continuously required throughout B cell development to reinforce commitment, as inactivation of Pax5 in mature B cells results in their de-differentiation to a progenitor stage that is capable of multi-lineage potential.
  • The reliance of B cell identity on a single gene is not without its problems as the loss of Pax5 results in B cell malignancies in mouse models and mutation in human PAX5 is the most-common genetic lesion in acute lymphoblastic leukemia.
  • [MeSH-major] B-Cell-Specific Activator Protein / physiology. B-Lymphocytes / cytology. Gene Expression Regulation
  • [MeSH-minor] Animals. Cell Differentiation. Cell Lineage. Disease Models, Animal. Hematopoietic Stem Cells / cytology. Humans. Mice. Models, Biological. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293359.001).
  • [ISSN] 1521-1878
  • [Journal-full-title] BioEssays : news and reviews in molecular, cellular and developmental biology
  • [ISO-abbreviation] Bioessays
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human
  • [Number-of-references] 34
  •  go-up   go-down


7. Vlădăreanu AM, Onisâi M, Ciufu C, Bumbea H, Cîşleanu D, Voican I, Nicolescu A, Radeşi S, Vintilescu A, Băluţă C, Dobrea C, Savlovschi C, Grecu L, Serban D, Serafim G: Splenectomy--a therapeutic option in splenic marginal zone cell lymphoma. Rom J Intern Med; 2009;47(2):191-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenectomy--a therapeutic option in splenic marginal zone cell lymphoma.
  • Lymph node and bone marrow biopsy together with flowcytometry established the diagnosis of Malignant non-Hodgkin Lymphoma--Atypical Splenic Marginal Zone B-cell lymphoma (aberrant expression of CD5) stage IVB, with leukemic picture, complicated with autoimmune hemolytic anemia with highly positive Coombs' tests.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / surgery. Splenectomy. Splenic Neoplasms / pathology. Splenic Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067170.001).
  • [ISSN] 1220-4749
  • [Journal-full-title] Romanian journal of internal medicine = Revue roumaine de médecine interne
  • [ISO-abbreviation] Rom J Intern Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


8. Terpos E, Politou M, Viniou N, Rahemtulla A: Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma; 2005 Dec;46(12):1699-707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Macrophage inflammatory protein-1 alpha (MIP-1alpha) is a member of the CC chemokine family and is primarily associated with cell adhesion and migration.
  • MIP-1alpha protein levels were elevated in the bone marrow plasma of MM patients and correlated with disease stage and activity.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263571.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Chemokine CCL3; 0 / Chemokine CCL4; 0 / Macrophage Inflammatory Proteins; 0 / Membrane Glycoproteins; 0 / RANK Ligand; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / TNFRSF11A protein, human; 0 / TNFSF11 protein, human; 0 / Tnfrsf11a protein, mouse; 0 / Tnfsf11 protein, mouse
  • [Number-of-references] 44
  •  go-up   go-down


9. Guillaume N, Gouilleux-Gruart V, Claisse JF, Troussard X, Lepelley P, Damaj G, Royer B, Garidi R, Lefrere JJ: Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia. Leuk Lymphoma; 2007 Aug;48(8):1556-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.
  • ZAP-70 and CD38 expression can identify B-cell chronic lymphocytic leukemia with an inferior clinical outcome.
  • Forty-one untreated and stage A patients, either ZAP-70(+)CD38(+) or ZAP-70(-)CD38(-), were tested to determine the MDR1 status.
  • [MeSH-major] Antigens, CD38 / metabolism. Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Membrane Glycoproteins / metabolism. P-Glycoprotein / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Aug;48(8):1468-9 [17701575.001]
  • (PMID = 17701587.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Membrane Glycoproteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


10. Na II, Kang HJ, Park YH, Lee SS, Yoo HJ, Choe DH, Ryoo BY, Yang SH: Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia. Eur J Haematol; 2007 Jul;79(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia.
  • This study evaluated the applicability of prognostic factors commonly used for diagnosis of classical lymphoma outcomes to extranodal NK/T cell lymphoma, nasal type (NTCL).
  • RLDH was associated with stage (I-II vs. III-IV), lymph node involvement (LNI), and International Prognostic Index score (<2 vs. > or =2).
  • Poor performance status and advanced stage were common in patients with local tumor invasiveness (LTI).
  • In multivariate analysis, the predictive values of LDH level, B symptom, performance status, and stage remained significant whereas those of LTI and LNI did not.
  • [MeSH-major] Killer Cells, Natural / immunology. Lymphoma, T-Cell / classification. Nose Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598834.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


11. Pope E, Weitzman S, Ngan B, Walsh S, Morel K, Williams J, Stein S, Garzon M, Knobler E, Lieber C, Turchan K, Wargon O, Tsuchiya A: Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma. J Cutan Med Surg; 2010 Jan-Feb;14(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma.
  • BACKGROUND/OBJECTIVES: There are limited data on the clinical presentation and progression of pediatric cutaneous lymphoma.
  • The most common MF presentation was patch stage (68%), followed by hypopigmentation (59%) and plaque stage disease (50%).
  • All patients presented with early-stage disease and received skin-directed therapy (topical steroids, 73%; light therapy, 54%; or combination therapy, 35%).
  • CONCLUSIONS: Pediatric patients with MF present in the first decade of life, with early-stage disease and unusual forms such as hypopigmented variant.
  • Further patient enrollment will provide information regarding natural history, treatment response, and overall prognosis of pediatric cutaneous T-cell lymphoma (CTCL).
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / epidemiology. Mycosis Fungoides / epidemiology. Skin Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20128983.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U, Saura Grau S, Rodríguez Franco C: Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. Clin Transl Oncol; 2009 Sep;11(9):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma.
  • BACKGROUND: The results of CHOP-21 (cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days) for the treatment of aggressive B-cell lymphoma have recently been improved by the addition of rituximab and by increasing the dose density.
  • PATIENTS AND METHODS: We present our experience with R-CHOP-14 in a retrospective single-centre review of 50 patients consecutively treated for aggressive B-cell lymphoma.
  • Stage III-IV was present in 62% of the patients and international prognostic index was high-to-intermediate risk or high risk in 32% of the patients.
  • CONCLUSIONS: In our experience the combination of RCHOP- 14 is highly effective in patients with aggressive B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1281-8 [6387060.001]
  • [Cites] Acta Haematol. 2006;115(1-2):22-7 [16424645.001]
  • [Cites] Hematol Oncol. 2008 Mar;26(1):27-32 [17868190.001]
  • [Cites] Leuk Lymphoma. 2005 Apr;46(4):541-7 [16019482.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Haematologica. 2006 Apr;91(4):496-502 [16537117.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • (PMID = 19776000.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Khodabakhshi R, Yahyazadeh-Jabbari SH, Gohari MR, Shahidi J, Ameri A: Treatment and prognosis of epithelial ovarian cancer: five year multi-center study. Saudi Med J; 2008 Dec;29(12):1735-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: From a total of 98 patients, there were 81 (82.6%) epithelial, 12 (12.2%) germ cell, 4 (4.1%) granulosa cell tumors, and one case of lymphoma.
  • Stage III was the most common stage (44.9%).
  • The most important prognostic factors were the initial stage (p=0.034), and the extent of surgical procedure (p=0.045).
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy


14. Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A: Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol; 2010 Dec 1;28(34):5074-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.
  • PURPOSE: High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL).
  • Patients with stage IV, early relapse, multiple relapse, anemia, or B symptoms had a higher risk of recurrence (P < .001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Kaplan-Meier Estimate. Methotrexate / administration & dosage. Methotrexate / adverse effects. Peripheral Blood Stem Cell Transplantation. Prognosis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975066.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Nemajerova A, Palacios G, Nowak NJ, Matsui S, Petrenko O: Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. PLoS One; 2009;4(11):e7784
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis.
  • We show here that p73 acts as a T cell-specific tumor suppressor in a genetically defined mouse model, and that concomitant ablation of p53 and p73 predisposes mice to an increased incidence of thymic lymphomas compared to the loss of p53 alone.
  • Our results demonstrate a causal role for loss of p73 in progression of T cell lymphomas to the stage of aggressive, disseminated disease.
  • We provide evidence that tumorigenesis in mice lacking p53 and p73 proceeds through mechanisms involving altered patterns of gene expression, defects in early T cell development, impaired apoptosis, and the ensuing accumulation of chromosomal aberrations.
  • Collectively, our data imply that tumor suppressive properties of p73 are highly dependent on cellular context, wherein p73 plays a major role in T cell development and neoplasia.
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Deletion. Lymphoma / metabolism. Nuclear Proteins / genetics. T-Lymphocytes / cytology. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Mar 2;404(6773):99-103 [10716451.001]
  • [Cites] Mutat Res. 2009 Jan 15;660(1-2):22-32 [19000702.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S45-55 [11983152.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):605-15 [12154353.001]
  • [Cites] Int J Cancer. 2002 Nov 1;102(1):15-9 [12353228.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39156-62 [12114514.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):533-9 [12717433.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5540-55 [12897129.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5642-51 [14654547.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):626-33 [14760085.001]
  • [Cites] Nat Rev Immunol. 2004 Apr;4(4):278-89 [15057786.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2449-60 [15059898.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):36-51 [15120909.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):1069-75 [14754877.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):85-9 [15261144.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Mol Carcinog. 1995 Sep;14(1):16-22 [7546219.001]
  • [Cites] Genes Dev. 1996 Mar 1;10(5):553-65 [8598286.001]
  • [Cites] Genes Dev. 1996 Aug 15;10(16):2038-54 [8769647.001]
  • [Cites] Genes Dev. 1996 Aug 15;10(16):2055-66 [8769648.001]
  • [Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4408-13 [9331104.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3352-6 [10416592.001]
  • [Cites] Immunity. 1999 Jul;11(1):91-101 [10435582.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8882-90 [15604248.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):363-73 [15837625.001]
  • [Cites] Mutat Res. 2005 Aug 25;576(1-2):4-21 [16038709.001]
  • [Cites] Oncogene. 2005 Aug 18;24(35):5521-4 [16007185.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):109-20 [16473278.001]
  • [Cites] Nat Rev Immunol. 2007 Jan;7(1):64-75 [17170755.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):165-8 [17332760.001]
  • [Cites] Oncogene. 2007 Aug 9;26(36):5280-9 [17325664.001]
  • [Cites] Mol Cell. 2007 Aug 17;27(4):647-59 [17707235.001]
  • [Cites] Genet Med. 2007 Sep;9(9):585-95 [17873646.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3102-11 [17656647.001]
  • [Cites] Genes Dev. 2008 Oct 1;22(19):2677-91 [18805989.001]
  • [Cites] EMBO J. 2002 Mar 15;21(6):1447-55 [11889050.001]
  • (PMID = 19907659.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ PMC2771421
  •  go-up   go-down


16. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P: Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci; 2009 Aug;41(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.
  • Patients' characteristics, including age, sex, stage of the underlying disease (complete or partial remission), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization.
  • Therefore, a patient who fails a first mobilization (and when an HLA-compatible related on unrelated donor is not available) could undergo a second attempt either with different mobilization schedule or by using different GF, such as stem cell factor, growth hormone (GH), or more recently newly introduced drugs such as AMD3100, alone or in combination with rHuG- or -rHuGM-CSF.
  • [MeSH-major] Neoplasms / surgery. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem Cell Mobilization / methods. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / surgery. Lymphoma, Non-Hodgkin / surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540167.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


17. Peled JU, Sellers RS, Iglesias-Ussel MD, Shin DM, Montagna C, Zhao C, Li Z, Edelmann W, Morse HC 3rd, Scharff MD: Msh6 protects mature B cells from lymphoma by preserving genomic stability. Am J Pathol; 2010 Nov;177(5):2597-608
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Msh6 protects mature B cells from lymphoma by preserving genomic stability.
  • Most human B-cell non-Hodgkin's lymphomas arise from germinal centers.
  • Reminiscent of the neoplasms arising in patients with Lynch syndrome III, mice deficient in MSH6 die prematurely of lymphoma.
  • In this study, we characterized the B-cell tumors in MSH6-deficient mice and describe their histological, immunohistochemical, and molecular features, which include moderate microsatellite instability.
  • Based on histological markers and gene expression, the tumor cells seem to be at or beyond the germinal center stage.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4126-31 [12651942.001]
  • [Cites] Blood. 2003 May 1;101(9):3574-80 [12511417.001]
  • [Cites] Immunol Rev. 2003 Aug;194:177-95 [12846815.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3894-8 [12873980.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):89-96 [10072354.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6850-5 [10359802.001]
  • [Cites] Immunity. 1999 Sep;11(3):309-16 [10514009.001]
  • [Cites] Am J Hum Genet. 1999 Nov;65(5):1291-8 [10521294.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):251-62 [15803153.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2626-35 [15805259.001]
  • [Cites] J Pathol. 2005 May;206(1):76-86 [15772984.001]
  • [Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]
  • [Cites] Annu Rev Biochem. 2005;74:681-710 [15952900.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3544-53 [15688022.001]
  • [Cites] Mol Carcinog. 2005 Dec;44(4):285-92 [16240453.001]
  • [Cites] Fam Cancer. 2005;4(4):323-33 [16341812.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):7837-47 [16339519.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):63-72 [16380510.001]
  • [Cites] Chem Rev. 2006 Feb;106(2):302-23 [16464007.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):682-92 [16332722.001]
  • [Cites] Oncologist. 2006 Apr;11(4):384-92 [16614234.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2531-6 [16331258.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):335-46 [16612326.001]
  • [Cites] FEBS J. 2006 Oct;273(19):4504-15 [16956364.001]
  • [Cites] Curr Biol. 2006 Sep 19;16(18):R808-10 [16979551.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6379-85 [17085649.001]
  • [Cites] Science. 2007 Jan 26;315(5811):528-31 [17185562.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1616-20 [17251349.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2439-47 [17363561.001]
  • [Cites] Lancet Neurol. 2007 Apr;6(4):340-51 [17362838.001]
  • [Cites] Int Immunol. 2007 Apr;19(4):545-56 [17329233.001]
  • [Cites] Mol Cell. 2007 May 25;26(4):565-78 [17531814.001]
  • [Cites] Mol Cell. 2007 May 25;26(4):579-92 [17531815.001]
  • [Cites] Clin Genet. 2007 Jun;71(6):499-500 [17539898.001]
  • [Cites] Nat Immunol. 2007 Jul;8(7):705-14 [17558410.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10956-61 [17573527.001]
  • [Cites] Nucleic Acids Res. 2007;35(12):4114-23 [17567610.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1989-98 [17664295.001]
  • [Cites] Nat Immunol. 2007 Oct;8(10):1132-9 [17828269.001]
  • [Cites] J Immunol. 2007 Nov 15;179(10):6808-19 [17982071.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2427-33 [17804422.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2889-95 [12960311.001]
  • [Cites] Mol Carcinog. 2003 Dec;38(4):155-9 [14639654.001]
  • [Cites] Nat Immunol. 2004 Feb;5(2):224-9 [14716311.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):17-25 [15236168.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):47-59 [15238604.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):61-8 [15238605.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):91-9 [15264277.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):139-50 [15324697.001]
  • [Cites] Nat Immunol. 2004 Nov;5(11):1117-23 [15489857.001]
  • [Cites] Gene. 1994 Sep 30;147(2):157-60 [7926794.001]
  • [Cites] Curr Biol. 1994 Jul 1;4(7):573-83 [7953531.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4B):1635-9 [7979199.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Cell. 1995 Jul 28;82(2):321-30 [7628020.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):64-70 [7550317.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3842-9 [8706033.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):312-5 [8896561.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2276-82 [9116269.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26382-7 [9334212.001]
  • [Cites] Cell. 1997 Nov 14;91(4):467-77 [9390556.001]
  • [Cites] Genetics. 1998 Apr;148(4):1637-46 [9560383.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4677-85 [9616165.001]
  • [Cites] Science. 1998 Jun 12;280(5370):1750-2 [9624052.001]
  • [Cites] Leukemia. 1998 Jun;12(6):845-59 [9639410.001]
  • [Cites] Immunity. 1998 Jul;9(1):127-34 [9697842.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):62-72 [17851451.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):22-33 [18097447.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]
  • [Cites] Nature. 2008 Feb 14;451(7180):841-5 [18273020.001]
  • [Cites] Annu Rev Immunol. 2008;26:481-511 [18304001.001]
  • [Cites] Annu Rev Immunol. 2008;26:261-92 [18370922.001]
  • [Cites] Biochemistry. 2008 Jun 10;47(23):6199-207 [18484749.001]
  • [Cites] PLoS Genet. 2008 Jun;4(6):e1000092 [18551179.001]
  • [Cites] J Immunol. 2008 Jul 15;181(2):1299-306 [18606684.001]
  • [Cites] DNA Repair (Amst). 2008 Aug 2;7(8):1392-8 [18562254.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4752-6 [18408759.001]
  • [Cites] Hum Genet. 2008 Sep;124(2):105-22 [18709565.001]
  • [Cites] J Exp Med. 2008 Sep 1;205(9):1949-57 [18678733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16248-53 [18854411.001]
  • [Cites] DNA Repair (Amst). 2009 Jan 1;8(1):137-41 [18952008.001]
  • [Cites] Genet Med. 2009 Jan;11(1):42-65 [19125127.001]
  • [Cites] Blood. 2009 Jul 16;114(3):547-54 [19478044.001]
  • [Cites] J Immunol. 2009 Sep 1;183(5):3188-94 [19648273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18698-703 [19837692.001]
  • [Cites] Nat Rev Clin Oncol. 2010 Apr;7(4):197-208 [20177404.001]
  • [Cites] Haematologica. 2010 May;95(5):841-4 [20015892.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):359-62 [10545954.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):579-84 [10662804.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1767-72 [10688836.001]
  • [Cites] Lab Invest. 2000 Feb;80(2):159-69 [10701686.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):803-7 [10706084.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2719-21 [10753856.001]
  • [Cites] Leuk Res. 2000 Aug;24(8):719-32 [10936424.001]
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Cell. 2000 Sep 1;102(5):565-75 [11007475.001]
  • [Cites] J Exp Med. 2000 Dec 18;192(12):1833-40 [11120779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7934-42 [11691815.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):26-37 [11709755.001]
  • [Cites] Bioinformatics. 2002 Jan;18(1):207-8 [11836235.001]
  • [Cites] J Exp Med. 2002 May 6;195(9):1187-92 [11994423.001]
  • [Cites] J Exp Med. 2002 May 6;195(9):1193-8 [11994424.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • (PMID = 20934970.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA013330; United States / NCI NIH HHS / CA / CA072649-13; United States / NCI NIH HHS / CA / R01-CA72649; United States / NCI NIH HHS / CA / R01 CA072649-13; United States / NCI NIH HHS / CA / R01 CA093484; United States / NCI NIH HHS / CA / R01-CA102705; United States / NCI NIH HHS / CA / R01 CA076329; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA102705; United States / NCI NIH HHS / CA / R01 CA102705-08; United States / NCI NIH HHS / CA / R01-CA76329; United States / NIGMS NIH HHS / GM / T32 GM007288; United States / NCI NIH HHS / CA / R01 CA072649; United States / NCI NIH HHS / CA / R01-CA93484; United States / NCI NIH HHS / CA / CA102705-08; United States / NCI NIH HHS / CA / P30 CA013330; United States / NIGMS NIH HHS / GM / T32-GM007288
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  • [Other-IDs] NLM/ PMC2966815
  •  go-up   go-down


18. Blijlevens NM, Donnelly JP, de Pauw BE: Microbiologic consequences of new approaches to managing hematologic malignancies. Rev Clin Exp Hematol; 2005 Dec;9(2):E2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the growing use of potent immunosuppressive purine analogues, fludarabine, pentostatin and cladibrine, and anti-T and anti-B cell antibodies, such as rituximab and campath, in the management of lymphoreticular malignancies, in combination with increasing emphasis on dose intensity, the number of patients at risk has almost reached levels encountered in recipients of allogenic stem cell grafts as a consequence of long-lasting deficiencies in the cellular immunity.
  • The spectrum of opportunistic pathogens are shifting as anti-leukemic and anti-lymphoma therapy become more intensive and bone marrow transplant practices evolve.
  • During the past decades we have even observed an increased incidence of invasive fungal infections in patients who are not in an end stage of their underlying disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864116.001).
  • [ISSN] 1825-151X
  • [Journal-full-title] Reviews in clinical and experimental hematology
  • [ISO-abbreviation] Rev Clin Exp Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 85
  •  go-up   go-down


19. Nguyen XC, Lee WW, Amin AM, Eo JS, Bang SM, Lee JS, Kim SE: Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma. Nucl Med Mol Imaging; 2010 Apr;44(1):39-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma.
  • PURPOSE: It is uncertain whether the tumor burden as assessed using FDG-PET has prognostic significance in newly diagnosed diffuse large B-cell lymphoma (DLBCL).
  • MATERIALS AND METHODS: Forty-two DLBCL patients (age, 57.4 ± 15.5 years; male/female = 25/17; stage I/II/III/IV=5/17/10/10) who underwent FDG-PET before chemotherapy were enrolled.
  • Among six variables [Ann Arbor stage, %Ki-67 expression, International Prognostic Index (IPI), MaxSUV, greatest diameter, and SIMaxSUV] investigated, only SIMaxSUV was found to be a single determinant of progression-free and overall survivals by multivariate analyses (p < 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24899936.001).
  • [ISSN] 1869-3474
  • [Journal-full-title] Nuclear medicine and molecular imaging
  • [ISO-abbreviation] Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC4042962
  • [Keywords] NOTNLM ; FDG-PET / Greatest diameter / Lymphoma / Prognosis / SUV / Size-incorporated maxSUV
  •  go-up   go-down


20. Nosari A, Tedeschi A, Ricci F, Montillo M: Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica; 2008 Feb;93(2):e30-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.
  • We have treated 67 patients, 8 non-Hodgkin's lymphoma and 59 chronic lymphocytic leukemia (CLL) with campath.
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Cell Count. Drug Administration Schedule. Female. Humans. Immune System / cytology. Male. Middle Aged. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Haematologica. 2007 Jun;92(6):784-94 [17550851.001]
  • (PMID = 18245646.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


21. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Call TG, Slager SL, Bowen DA, Schwager SM, Nowakowski GS: Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma; 2010 Jul;51(7):1233-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia.
  • Statins and non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications.
  • In vitro studies suggest that statins and NSAIDs may have potential as anticancer therapies in low-grade non-Hodgkin lymphomas including chronic lymphocytic leukemia (CLL), and a recent observational study found statin use was associated with improved event free survival in patients with follicular lymphoma.
  • We therefore conducted an observational cohort study of 686 patients with newly diagnosed Rai stage 0 CLL to evaluate whether statin or NSAID use was related to their clinical outcome or influenced the efficacy of rituximab therapy.
  • Although previous studies suggested statins may improve event free survival among patients with follicular lymphoma, we find no impact of statins on time to initial therapy in this large study of patients with Rai stage 0 CLL.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2007 Nov;139(3):398-404 [17910629.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2412-7 [18067017.001]
  • [Cites] Cancer Immunol Immunother. 2008 Mar;57(3):347-58 [17668203.001]
  • [Cites] Leuk Lymphoma. 2008 Jan;49(1):49-56 [18203011.001]
  • [Cites] Invest New Drugs. 2008 Apr;26(2):139-49 [18094935.001]
  • [Cites] PLoS Med. 2008 Mar 25;5(3):e64 [18366248.001]
  • [Cites] Atherosclerosis. 2008 Apr;197(2):829-39 [17826781.001]
  • [Cites] Br J Haematol. 2008 May;141(5):615-21 [18373706.001]
  • [Cites] Br J Haematol. 2008 May;141(5):607-14 [18384436.001]
  • [Cites] Ann Pharmacother. 2008 Sep;42(9):1208-15 [18648016.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5486; author reply 5486 [18936467.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2184-92 [18784741.001]
  • [Cites] N Engl J Med. 2009 Jan 8;360(2):192; author reply 193 [19129537.001]
  • [Cites] Lancet. 2009 Apr 11;373(9671):1301-9 [19328542.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):412-7 [20008638.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):337-44 [11790213.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5711-9 [12384529.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] Exp Hematol. 2003 Sep;31(9):779-83 [12962723.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1055-69 [12963986.001]
  • [Cites] Exp Cell Res. 1984 Jul;153(1):91-8 [6610562.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Mar 30;199(3):1209-15 [8147861.001]
  • [Cites] Lipids. 1997 Mar;32(3):255-62 [9076662.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1406-14 [9694730.001]
  • [Cites] Atheroscler Suppl. 2004 Oct;5(3):67-80 [15531278.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]
  • [Cites] Blood. 2005 Jul 15;106(2):650-7 [15802535.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1216-23 [15858619.001]
  • [Cites] Clin Immunol. 2006 Jul;120(1):76-90 [16473553.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3218-9; author reply 3219-20 [16809747.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):1053-61 [16840197.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4634-41 [17008705.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2625-34 [17169808.001]
  • [Cites] Immunology. 2007 Mar;120(3):315-24 [17140403.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Sep;60(4):545-53 [17186240.001]
  • (PMID = 20496995.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / CA113408
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ NIHMS549713; NLM/ PMC3913168
  •  go-up   go-down


22. [Case report of synchronous manifestation of two malignant tumors--cervical cancer and malignant lymphoma]. Akush Ginekol (Sofiia); 2010;49(5):64-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of synchronous manifestation of two malignant tumors--cervical cancer and malignant lymphoma].
  • Affected lymph nodes in cervical cancer is different and depends on the stage and histological type of tumor (squamous and adenocarcinoma) and is an important prognostic factor.
  • Malignant non-Hodgkin's lymphoma populations (NHL) originale from the lymph organs and from their populations downstream lymphoid Stem cell to mature lymphocytes that have opportunities for transformation and proliferation.
  • We present the random case developed cervical cancer and malignant lymphoma.
  • [MeSH-major] Lymphoma / pathology. Uterine Cervical Neoplasms / pathology


23. Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen S, Cathomas R: Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie; 2009 Oct;32(10):586-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary manifestation of small lymphocytic lymphoma in the prostate.
  • BACKGROUND: Infiltration of non-haematopoietic organs by small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL) is not unusual in late-stage disease and thus quite frequently encountered in post-mortem examinations.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2009 Oct;32(10):550-1 [19816069.001]
  • (PMID = 19816076.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 17
  •  go-up   go-down


24. Pedersen LM, Jürgensen GW, Johnsen HE: Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. Br J Haematol; 2005 Mar;128(6):813-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
  • Circulating inflammatory cytokines have a prognostic impact independent of the information provided by the International Prognostic Index (IPI) in diffuse large B-cell lymphoma (DLBCL).
  • The present study characterized prognostic cytokines in relation to stage-specific B-cell differentiation antigens and bcl-2 protein expression, assessed by immunohistochemistry in de novo DLBCL.
  • Serum levels of interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-alpha) were found to be significantly lower in patients with a germinal centre (GC) phenotype (co-expression of bcl-6 and CD10) compared with the non-GC phenotype.
  • However, IL-6 and VEGF, combined with non-GC phenotype and bcl-2 positivity, respectively, had a similar independent prognostic power as the IPI.
  • In conclusion, our data suggest that inflammatory cytokines are differently distributed in the GC and non-GC phenotypes and correlate to bcl-2 expression.
  • [MeSH-major] Cytokines / metabolism. DNA-Binding Proteins / metabolism. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood. Neprilysin / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755285.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


25. Fujita Y, Abe R, Sasaki M, Honda A, Furuichi M, Asano Y, Norisugi O, Shimizu T, Shimizu H: Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides. Clin Cancer Res; 2006 May 1;12(9):2670-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides.
  • PURPOSE: Mycosis fungoides (MF), a common type of cutaneous T cell lymphoma with an indolent clinical course, has the characteristic that malignant T cell clones are recruited into the skin from the early disease stages.
  • Recently, CCR10 and CTACK/CCL27 were proposed to play a role in the recruitment of other types of cutaneous T cell lymphoma.

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16675558.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL27 protein, human; 0 / CCR10 protein, human; 0 / Chemokine CCL27; 0 / Chemokines, CC; 0 / Receptors, CCR10; 0 / Receptors, Chemokine
  •  go-up   go-down


26. Gokhale CD, Udipi SA, Ambaye RY, Pai SK, Advani SH: Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Am Coll Nutr; 2007 Feb;26(1):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL).
  • Comparisons were made to stage of treatment (maintenance 6 with post-therapy), type of treatment (chemotherapy and radiation with only chemotherapy) and type of malignancy (ALL with NHL).
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood


27. Valsami S, Pappa V, Rontogianni D, Kontsioti F, Papageorgiou E, Dervenoulas J, Karmiris T, Papageorgiou S, Harhalakis N, Xiros N, Nikiforakis E, Economopoulos T: A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica; 2007 Oct;92(10):1343-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4.
  • BACKGROUND AND OBJECTIVES: Although most patients with classical Hodgkin's lymphoma (CHL) are cured, a significant minority are refractory to treatment.
  • The aim of our study was to detect B-cell differentiation markers and transcription factors in CHL in order to define subgroups with different histogeneses and prognoses.
  • DESIGN AND METHODS: We evaluated 107 cases of CHL for BCL6, CD79a, MUM1/IRF4 and B-cell transcription factors BOB.1, OCT.2 expression by immunohistochemistry.
  • Univariate analysis showed that age of 45 or more, stage III and IV disease and MUM/IRF4 negative status were associated with significantly shorter time to progression (TTP) and overall survival (OS).
  • [MeSH-major] Cell Differentiation. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Interferon Regulatory Factors / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768115.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interferon Regulatory Factors; 0 / Transcription Factors; 0 / interferon regulatory factor-4
  •  go-up   go-down


28. Lee YS, Dutta A: MicroRNAs in cancer. Annu Rev Pathol; 2009;4:199-227
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pattern of miRNA expression can be correlated with cancer type, stage, and other clinical variables, so miRNA profiling can be used as a tool for cancer diagnosis and prognosis. miRNA expression analyses also suggest oncogenic (or tumor-suppressive) roles of miRNAs. miRNAs play roles in almost all aspects of cancer biology, such as proliferation, apoptosis, invasion/metastasis, and angiogenesis.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2240-52 [17242205.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2345-50 [17332367.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8256-64 [17220301.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):16635-41 [15722555.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):280-5 [15648093.001]
  • [Cites] Trends Genet. 2005 Jun;21(6):322-6 [15922829.001]
  • [Cites] Immunol Cell Biol. 2007 Aug-Sep;85(6):458-62 [17621315.001]
  • [Cites] Oncogene. 2007 Sep 6;26(41):6099-105 [17384677.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6133-40 [17404574.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Nat Cell Biol. 2005 Jul;7(7):719-23 [15937477.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):766-70 [15965474.001]
  • [Cites] Science. 2005 Jul 8;309(5732):310-1 [15919954.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Science. 2001 Oct 26;294(5543):858-62 [11679671.001]
  • [Cites] Science. 2001 Oct 26;294(5543):862-4 [11679672.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2056-60 [12154197.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2491-6 [12368260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Science. 2002 Dec 20;298(5602):2283 [12493874.001]
  • [Cites] RNA. 2003 Mar;9(3):277-9 [12592000.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):415-9 [14508493.001]
  • [Cites] Cell. 2003 Oct 17;115(2):199-208 [14567917.001]
  • [Cites] Cell. 2003 Oct 17;115(2):209-16 [14567918.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3011-6 [14681208.001]
  • [Cites] Science. 2004 Jan 2;303(5654):95-8 [14631048.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3087-95 [15126345.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Genome Res. 2004 Oct;14(10A):1902-10 [15364901.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2657-64 [2548084.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cell. 1993 Dec 3;75(5):855-62 [8252622.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Trends Biochem Sci. 1998 Jun;23(6):198-9 [9644970.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):235-40 [15531877.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):231-5 [15531879.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):226-30 [15538371.001]
  • [Cites] RNA. 2004 Dec;10(12):1957-66 [15525708.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Cell. 2005 Jan 14;120(1):21-4 [15652478.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):111-5 [15723655.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Cell. 2005 Mar 11;120(5):623-34 [15766526.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):338-45 [15735639.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8433-8 [17823410.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2631-40 [17586726.001]
  • [Cites] RNA. 2007 Oct;13(10):1668-74 [17698639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15484-9 [17855557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 [17875987.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8994-9000 [17908999.001]
  • [Cites] Dev Biol. 2007 Oct 15;310(2):442-53 [17765889.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10 [17890317.001]
  • [Cites] Cancer Sci. 2007 Dec;98(12):1845-52 [17888029.001]
  • [Cites] Cancer Sci. 2007 Dec;98(12):1914-20 [17892514.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Cell. 2005 Aug 26;122(4):553-63 [16122423.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1577-81 [16141076.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2135-43 [17135249.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2130-4 [17135268.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):336-47 [17243163.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1859-67 [17194750.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1424-9 [17308079.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):410-2 [17325905.001]
  • [Cites] Nature. 2005 Dec 1;438(7068):685-9 [16258535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Nucleic Acids Res. 2006;34(2):e9 [16434699.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1277-81 [16452179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Gene Ther. 2006 Mar;13(6):496-502 [16195701.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92 [16505370.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Nucleic Acids Res. 2006;34(6):1765-71 [16582102.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2014-24 [16609010.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2537-45 [16331254.001]
  • [Cites] Gene. 2006 May 10;372:137-41 [16503100.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):497-508 [16728577.001]
  • [Cites] Cell. 2006 Jun 2;125(5):887-901 [16751099.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6097-104 [16778182.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):813-8 [16751773.001]
  • [Cites] RNA. 2006 Jul;12(7):1161-7 [16738409.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2202-7 [16882971.001]
  • [Cites] Mol Cancer. 2006;5:29 [16854228.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] J Cell Biol. 2006 Aug 28;174(5):677-87 [16923828.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91 [16822819.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Oct 13;349(1):59-68 [16934749.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9090-8 [16982751.001]
  • [Cites] J Cell Biochem. 2006 Oct 15;99(3):671-8 [16924677.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4677-84 [16966691.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8191-201 [16940181.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10843-8 [17108120.001]
  • [Cites] PLoS Biol. 2006 Jul;4(7):e210 [16756390.001]
  • [Cites] J Cell Physiol. 2007 Feb;210(2):370-7 [17111382.001]
  • [Cites] Nat Struct Mol Biol. 2006 Dec;13(12):1097-101 [17099701.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] J Virol. 2007 Jan;81(2):1033-6 [17079300.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1479-86 [17110380.001]
  • [Cites] Cell Cycle. 2006 Dec;5(24):2835-8 [17172864.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19983-8 [18056640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] RNA. 2008 Jan;14(1):35-42 [18025253.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11612-20 [18089790.001]
  • [Cites] Immunity. 2007 Dec;27(6):825-7 [18093533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20350-5 [18077375.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1931-4 [18048652.001]
  • [Cites] Methods. 2008 Jan;44(1):22-30 [18158129.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2456-68 [17363563.001]
  • [Cites] Science. 2007 Mar 16;315(5818):1576-9 [17322030.001]
  • [Cites] Genome Biol. 2007;8(2):R27 [17326821.001]
  • [Cites] Retrovirology. 2007;4:5 [17442096.001]
  • [Cites] Mol Endocrinol. 2007 May;21(5):1132-47 [17312270.001]
  • [Cites] Nat Genet. 2007 May;39(5):673-7 [17401365.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):633-6 [15908945.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Mol Cancer. 2007;6:5 [17222355.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1604-9 [17242365.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):976-83 [17283129.001]
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Methods. 2008 Jan;44(1):31-8 [18158130.001]
  • [Cites] Cell. 2007 Dec 28;131(7):1273-86 [18155131.001]
  • [Cites] Genome Biol. 2007;8(8):R166 [17697356.001]
  • [Cites] Nat Rev Genet. 2008 Feb;9(2):102-14 [18197166.001]
  • [Cites] Curr Protoc Mol Biol. 2008 Jan;Chapter 26:Unit26.7 [18231982.001]
  • [Cites] Genome Biol. 2007;8(10):R214 [17922911.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] Blood. 2007 May 15;109(10):4399-405 [17284533.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):8017-22 [17470785.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):7957-62 [17483472.001]
  • [Cites] Nucleic Acids Res. 2007;35(9):2885-92 [17439965.001]
  • [Cites] Mol Cell Biol. 2007 Jun;27(11):3970-81 [17403906.001]
  • [Cites] Nat Rev Genet. 2007 Jun;8(6):413-23 [17486121.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1483-91 [17483436.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Drug Discov Today. 2007 Jun;12(11-12):452-8 [17532529.001]
  • [Cites] Mol Cell Biol. 2007 Jun;27(12):4238-47 [17438130.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] Oncogene. 2007 May 31;26(26):3769-76 [17173072.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5148-55 [17545593.001]
  • [Cites] Neuron. 2007 Jun 7;54(5):813-29 [17553428.001]
  • [Cites] Science. 2007 Jun 8;316(5830):1484-8 [17510325.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):731-43 [17540598.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] World J Gastroenterol. 2007 May 28;13(20):2883-8 [17569129.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5699-707 [17575136.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1130-4 [17554337.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10980-5 [17581865.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1156-61 [17487835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11400-5 [17600087.001]
  • [Cites] Nature. 2007 Jul 5;448(7149):83-6 [17589500.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):91-105 [17612493.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6031-43 [17616659.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6092-9 [17616664.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6130-5 [17616669.001]
  • [Cites] Cell Cycle. 2007 Jul 1;6(13):1586-93 [17554199.001]
  • [Cites] J Pathol. 2007 Aug;212(4):368-77 [17471471.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5017-22 [17297439.001]
  • [Cites] Nucleic Acids Res. 2007;35(13):4535-41 [17584784.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):1033-7 [17643101.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1330-3 [17496199.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):647-58 [17681183.001]
  • [Cites] Curr Biol. 2007 Aug 7;17(15):1298-307 [17656095.001]
  • [Cites] EMBO J. 2007 Aug 8;26(15):3699-708 [17627278.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1482-90 [17608773.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7713-22 [17699775.001]
  • [Cites] Cell Cycle. 2007 Aug 15;6(16):2005-9 [17721077.001]
  • [Cites] Nat Methods. 2007 Sep;4(9):721-6 [17694064.001]
  • [Cites] Mol Cell. 2007 Oct 26;28(2):328-36 [17964270.001]
  • [Cites] Mol Cancer. 2007;6:54 [17716371.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):32773-9 [17724023.001]
  • [Cites] PLoS One. 2007;2(11):e1133 [17989771.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11001-11 [18006846.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19291-6 [18042700.001]
  • [Cites] Science. 2005 Oct 14;310(5746):317-20 [16224024.001]
  • [Cites] Leukemia. 2005 Nov;19(11):2013-6 [16167061.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1163-5 [16254559.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • (PMID = 18817506.001).
  • [ISSN] 1553-4014
  • [Journal-full-title] Annual review of pathology
  • [ISO-abbreviation] Annu Rev Pathol
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR053948-03; United States / NIAMS NIH HHS / AR / R01 AR053948; United States / NIAMS NIH HHS / AR / AR 053948; United States / NIAMS NIH HHS / AR / R01 AR053948-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  • [Number-of-references] 209
  • [Other-IDs] NLM/ NIHMS153379; NLM/ PMC2769253
  •  go-up   go-down


29. Reece D, Imrie K, Stevens A, Smith CA, Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care: Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Curr Oncol; 2006 Oct;13(5):160-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
  • QUESTIONS: In patients with multiple myeloma, Waldenström macroglobulinemia, or lymphoma, what is the efficacy of bortezomib alone or in combination as measured by survival, quality of life, disease control (for example, time to progression), response duration, or response rate?What is the toxicity associated with the use of bortezomib?Which patients are more or less likely to benefit from treatment with bortezomib?
  • No randomized trials were retrieved for lymphoma.
  • Bortezomib is recommended as the preferred treatment option in patients with myeloma relapsing within 1 year of the conclusion of initial treatment; it may also be a reasonable option in patients relapsing at least 1 year after autologous stem-cell transplantation.
  • PRACTICE GUIDELINE: This evidence-based series applies to adult patients with myeloma, Waldenström macroglobulinemia, or lymphoma of any type, stage, histology, or performance status.
  • RECOMMENDATIONS: Based on the results of a large well-conducted rct, which represents the only published randomized study in relapsed myeloma, the Hematology Disease Site Group (dsg) offers the following recommendations: For patients with myeloma refractory to or relapsing within 1 year of the conclusion of initial or subsequent treatment or treatments, including autologous stem-cell transplantation, and who are candidates for further chemotherapy, bortezomib is recommended as the preferred treatment option.Bortezomib is also a reasonable option for patients relapsing at least 1 year after autologous stem-cell transplantation.
  • However, evaluation of these other options is beyond the scope of this practice guideline.For patients with myeloma relapsing at least 1 year after the conclusion of alkylating agent-based chemotherapy who are candidates for further chemotherapy, further treatment with alkylating agent-based chemotherapy is recommended.Evidence is insufficient to support the use of bortezomib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia outside of clinical trials.
  • The Hematology dsg recognizes that thalidomide is an active agent in multiple myeloma patients who have relapsed after autologous stem-cell transplantation or who are refractory to alkylating agent-based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1986 Jul;105(1):8-11 [3717812.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Cancer. 1981 Apr 15;47(8):1923-9 [7226087.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Blood. 2004 Jul 15;104(2):336-9 [15054044.001]
  • [Cites] Blood. 2004 Aug 1;104(3):607-18 [15090448.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1386-95 [15155468.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1578-82 [16342650.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Blood. 2001 Jul 15;98(2):492-4 [11435324.001]
  • [Cites] Ann Intern Med. 2002 Apr 16;136(8):619-29 [11955031.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] N Engl J Med. 1984 May 24;310(21):1353-6 [6546971.001]
  • (PMID = 22792013.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3394599
  • [Keywords] NOTNLM ; Bortezomib / Velcade / clinical practice guideline / lymphoma / multiple myeloma / systematic review
  •  go-up   go-down


30. Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors. Blood; 2005 Feb 15;105(4):1660-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
  • Here, for the first time, we address the role of TIMP-1 in the pathogenesis of B-cell lymphomas.
  • An Epstein-Barr virus (EBV)-negative Burkitt lymphoma cell line with ectopic TIMP-1 expression (TIMP-1JD38) was used to identify genes induced/repressed by TIMP-1.
  • Analysis revealed changes of genes coding for B-cell growth/differentiation, transcription, and cell cycle regulators.
  • TIMP-1 repressed expression of germinal center (GC) markers CD10, Bcl-6, PAX-5 and up-regulated plasma cell-associated antigens CD138, MUM-1/IRF-4, XBP-1, and CD44, suggesting a plasma cell differentiation.
  • This incomplete plasmacytic differentiation occurs without altering cell proliferation, and despite c-Myc deregulation, indicating an arrested plasmacytic/plasmablastic stage of differentiation.
  • Further validation in human lymphoma cell lines and in primary B-cell tumors demonstrated a predominant TIMP-1 expression in tumors with plasmacytic/plasmablastic phenotypes, including multiple myelomas.
  • [MeSH-major] Burkitt Lymphoma / pathology. Cell Differentiation / physiology. Plasma Cells / pathology. Tissue Inhibitor of Metalloproteinase-1 / physiology
  • [MeSH-minor] B-Lymphocytes / cytology. B-Lymphocytes / enzymology. B-Lymphocytes / metabolism. Cell Cycle Proteins / antagonists & inhibitors. Cell Cycle Proteins / biosynthesis. Cell Line, Tumor. Cell Proliferation. Down-Regulation / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / physiology. Humans. Lymphoid Tissue / enzymology. Lymphoid Tissue / pathology. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Multiple Myeloma / enzymology. Multiple Myeloma / genetics. Oligonucleotide Array Sequence Analysis. Repressor Proteins / physiology. Transcription Factors / antagonists & inhibitors. Transcription Factors / biosynthesis. Transcription, Genetic / physiology. Up-Regulation / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15479729.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Repressor Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Transcription Factors
  •  go-up   go-down


31. Wessels G, Bernard Hesseling P: Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa. Transfus Apher Sci; 2005 Feb;32(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
  • Hodgkin's disease (HD) in children corresponds to a large degree to HD in adults.
  • Non-Hodgkin's Lymphoma (NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course.
  • For practical reasons clinicians generally classify and treat NHL in children as either B-cell or T-cell disease.
  • Lymphoblastic or T-cell NHL is treated with regimens normally used for acute lymphoblastic leukaemia (e.g.
  • BFM protocols) or modified leukaemia treatments for leukaemia-lymphoma syndromes (e.g. LSA2L2).
  • Three consecutive regimens have been used to treat B-cell NHL over the past 22 years.
  • Although toxicity has increased with the increased intensity of the treatment regimen, EFS has improved from 25% to 87% for all B-cell NHL.
  • The majority of patients had stage III and IV disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737871.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  • [Number-of-references] 15
  •  go-up   go-down


32. Weigert O, Dreyling M, Unterhalt M, Hiddemann W, Buske C: Investigational strategies in autologous stem cell transplantation for follicular lymphoma. Curr Oncol Rep; 2006 Sep;8(5):368-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigational strategies in autologous stem cell transplantation for follicular lymphoma.
  • Recent retrospective analyses indicate prolonged survival for patients with follicular lymphoma over the past 25 years, attributed most likely to improved supportive care and sequential application of effective therapies.
  • Encouraging results were obtained from several randomized trials evaluating myeloablative therapy followed by autologous stem cell transplantation (ASCT) as consolidation therapy applied to patients with advanced-stage follicular lymphoma either in first remission or as salvage therapy.
  • Combination of these novel strategies into a multimodal approach justifies hope that the treatment outcome of patients suffering from follicular lymphoma will be further improved.
  • [MeSH-major] Clinical Trials as Topic. Hematopoietic Stem Cell Transplantation. Lymphoma, Follicular / therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4926-33 [15611507.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):445-50 [9053464.001]
  • [Cites] Blood. 2005 May 15;105(10):3817-23 [15687232.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2934-42 [11049969.001]
  • [Cites] Blood. 1984 Jun;63(6):1424-33 [6609729.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3918-27 [14517188.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1460-8 [15084619.001]
  • [Cites] Blood. 2000 Aug 1;96(3):864-9 [10910898.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1504-8 [16690968.001]
  • [Cites] Bone Marrow Transplant. 2003 Aug;32(3):317-24 [12858205.001]
  • [Cites] Radiother Oncol. 2000 Jul;56(1):1-8 [10869748.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2351-7 [12750161.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1982 Apr;41(4):411-20 [7042622.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2896-902 [16002426.001]
  • [Cites] Blood. 1987 Feb;69(2):584-91 [3492224.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):947-55 [10694543.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):711-7 [15581541.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):527-36 [10653868.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]
  • [Cites] J Immunol. 1985 Aug;135(2):973-9 [3925015.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):461-7 [15534357.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):57-63 [12815479.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2 Suppl 4):10-21 [12728403.001]
  • [Cites] Semin Oncol. 1993 Oct;20(5 Suppl 5):75-88 [8211209.001]
  • (PMID = 16901398.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 48
  •  go-up   go-down


33. Bacon CM, Diss TC, Ye H, Liu H, Goatly A, Hamoudi R, Wotherspoon A, Gascoyne RD, Dogan A, Du MQ, Isaacson PG: Follicular lymphoma of the thyroid gland. Am J Surg Pathol; 2009 Jan;33(1):22-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma of the thyroid gland.
  • The majority of lymphomas arising in the thyroid gland are mucosa-associated lymphoid tissue lymphomas and diffuse large B-cell lymphomas, which arise from a background of chronic lymphocytic thyroiditis.
  • Follicular lymphoma may also present in the thyroid gland, but its clinicopathologic features at this site are not well characterized, leading to difficulties in diagnosis and clinical management.
  • All cases showed morphology characteristic of follicular lymphoma, however, in many the interfollicular neoplastic infiltrate was particularly prominent and all lymphomas contained readily identifiable and often striking lymphoepithelial lesions, features heretofore considered indicative of mucosa-associated lymphoid tissue lymphoma at this site.
  • In 1 group, similar to typical adult follicular lymphoma, cases carried a t(14;18)/IGH-BCL2 and/or expressed Bcl-2, and were mostly CD10-positive and of World Health Organization (WHO) grade 1 to 2.
  • The 2 groups differed in clinical stage at presentation, 11 patients in the former group but none in the latter group having disease beyond the thyroid gland.
  • Appreciation of the spectrum of morphologic, immunophenotypic, and genetic characteristics of follicular lymphoma presenting in the thyroid gland should aid both diagnosis and clinical management.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2008 Jan;29(1):25-33 [18061541.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Histopathology. 2000 Jul;37(1):10-8 [10931213.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):629-35 [11241227.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):647-55 [11821444.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2309-17 [12399977.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Int J Surg Pathol. 2001 Oct;9(4):287-93 [12574844.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2335-9 [12406890.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2489-95 [12456507.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1012-8 [12676782.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):307-13 [15233907.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):644-53 [15286744.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1722-6 [15356642.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Histopathology. 1978 May;2(3):201-13 [580930.001]
  • [Cites] Cancer. 1979 Aug;44(2):529-42 [383257.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Aug 23;383(3):293-317 [158873.001]
  • [Cites] Am J Clin Pathol. 1980 Jul;74(1):1-11 [7395811.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] N Engl J Med. 1985 Mar 7;312(10):601-4 [3838363.001]
  • [Cites] Histopathology. 1985 Jan;9(1):81-97 [3884481.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):100-4 [3708539.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] Blood. 1991 Aug 1;78(3):581-5 [1859876.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):929-33 [1555984.001]
  • [Cites] Am J Pathol. 1992 Jul;141(1):43-52 [1632470.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4 [1495966.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):1137-48 [1402658.001]
  • [Cites] Histopathology. 1994 Apr;24(4):323-7 [8045521.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Histopathology. 1996 Jan;28(1):25-32 [8838117.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4708-14 [9616169.001]
  • [Cites] Mod Pathol. 1998 Sep;11(9):864-9 [9758366.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):316-23 [10375088.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):263-70 [10439808.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):69-82 [15613857.001]
  • [Cites] J Pathol. 2005 Feb;205(3):329-35 [15682435.001]
  • [Cites] J Pathol. 2005 Feb;205(3):293-301 [15682443.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):1-10 [15694181.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):73-8 [15735858.001]
  • [Cites] Leukemia. 2005 Apr;19(4):652-8 [15703784.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1058-63 [15815725.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6358-63 [16155020.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):529-36 [16625101.001]
  • [Cites] Histopathology. 2006 Sep;49(3):229-41 [16918969.001]
  • [Cites] Histopathology. 2006 Oct;49(4):426-9 [16978207.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3076-9 [17138820.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1050-8 [17592272.001]
  • (PMID = 18830125.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274-069001; United States / NCI NIH HHS / CA / P50 CA097274-079001; United States / NCI NIH HHS / CA / CA097274-069001; United States / NCI NIH HHS / CA / CA097274-079001; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS80966; NLM/ PMC2673478
  •  go-up   go-down


34. Saif MW, Khubchandani S, Walczak M: Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis. World J Gastroenterol; 2007 Sep 28;13(36):4909-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis.
  • Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma.
  • However, a diffuse large B-cell lymphoma presenting as acute pancreatitis is rare.
  • Biopsy of the axillary mass revealed a large B-cell lymphoma.
  • The patient was classified as stage IV, based on the Ann Arbor Classification, and as having a high-risk lymphoma, based on the International Prognostic Index.
  • A literature search revealed only seven cases of primary involvement of the pancreas in B-cell lymphoma presenting as acute pancreatitis.
  • However, only one case of secondary pancreatic involvement by B-cell lymphoma presenting as acute pancreatitis has been published.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / etiology


35. Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, Hägglund H: Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol; 2008;25(4):374-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.
  • Late-onset neutropenia, i.e. an absolute neutrophil count of <1.5 x 10(9)/l, may follow 4 weeks or more after therapy with rituximab for lymphoma.
  • In a retrospective study of 113 consecutive lymphoma patients treated with rituximab, with or without chemotherapy, we found eight patients (7%) with late-onset neutropenia (LON).
  • Four of the eight patients underwent stem cell transplantation.
  • In four subsequently identified patients with severe LON, a maturation arrest at the (pro)myelocyte stage was observed in the bone marrow, similar to that found in severe congenital neutropenia or Kostmann disease.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cell Differentiation / drug effects. DNA Mutational Analysis. Female. Humans. Lymphoma / drug therapy. Male. Middle Aged. Proteins / genetics. Rituximab. Time

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 2002 Apr;39(2):113-20 [11957194.001]
  • [Cites] Eur J Haematol Suppl. 2007 Jan;(67):5-14 [17206982.001]
  • [Cites] Eur J Haematol Suppl. 1996;60:93-7 [8987249.001]
  • [Cites] Haematologica. 2007 Feb;92(2):e20-3 [17405749.001]
  • [Cites] Int J Hematol. 2006 Oct;84(3):242-7 [17050199.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):628-32 [11128813.001]
  • [Cites] Acta Paediatr. 2007 Jun;96(6):813-9 [17537008.001]
  • [Cites] Ann Pharmacother. 2005 Dec;39(12):2091-5 [16249269.001]
  • [Cites] Autoimmun Rev. 2006 Jan;5(1):18-24 [16338207.001]
  • [Cites] Curr Drug Metab. 2006 Apr;7(3):219-29 [16611018.001]
  • [Cites] Blood. 2005 Aug 1;106(3):795-802 [15718416.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):913-8 [12786803.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):1232-8 [16002727.001]
  • [Cites] Haematologica. 2004 Mar;89(3):361-3 [15020279.001]
  • [Cites] Acta Paediatr. 2006 Dec;95(12):1526-32 [17129957.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):1013-7 [16840190.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):597-600 [12007508.001]
  • [Cites] Bull Cancer. 2007 Feb;94(2):198-202 [17337389.001]
  • [Cites] Cancer Treat Rev. 2005 Oct;31(6):456-73 [16054760.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):635-8 [8757135.001]
  • [Cites] Semin Hematol. 2006 Jul;43(3):189-95 [16822461.001]
  • [Cites] Blood. 2004 May 1;103(9):3355-61 [14764541.001]
  • [Cites] Bone Marrow Transplant. 2004 May;33(9):921-3 [15034544.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):86-92 [17187068.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):275-8 [15813856.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4 [12826650.001]
  • (PMID = 18278570.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / HAX1 protein, human; 0 / Proteins; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


36. Strumane K, Rygiel TP, Collard JG: The Rac activator Tiam1 and Ras-induced oncogenesis. Methods Enzymol; 2006;407:269-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro studies indicate that Tiam1 localizes to adherens junctions and plays a role in the formation and maintenance of cadherin-based cell adhesions, thereby regulating migration of epithelial cells.
  • This two-stage carcinogenesis protocol allows us to study initiation, promotion, and progression of tumors in a Tiam1-positive and Tiam1-negative background.
  • Moreover, we describe methods to study the role of Tiam1 in susceptibility to apoptosis, cell growth, and Ras transformation by in vivo and in vitro experiments.
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Apoptosis / physiology. Cell Separation. Down-Regulation. Keratinocytes / cytology. Mice. Mice, Knockout. NIH 3T3 Cells. Skin Neoplasms / etiology. Skin Neoplasms / pathology


37. Schüler F, Hirt C, Dölken L, Krüger W, Dölken G: [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells]. Dtsch Med Wochenschr; 2005 Sep 23;130(38):2130-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
  • BACKGROUND AND OBJECTIVE: In patients with follicular lymphoma and mantle cell lymphoma circulating lymphoma cells can be detected by quantitative real-time PCR with a high sensitivity and reproducibility.
  • With this study we wanted to ascertain whether a continuous molecular remission achieved in patients with mantle cell lymphoma and follicular lymphoma has an impact on survival of these patients.
  • PATIENT AND METHODS: We conducted these investigations in 32 patients (24 with follicular lymphoma and 8 with mantle cell lymphoma) who were treated in a randomized trial with chemotherapy plus/minus rituximab (MCP, R-MCP).
  • A further ten patients had follicular lymphoma (stage I and II) in long-term complete remission after radiation therapy.
  • RESULTS: Up to 18 years after initial diagnoses of a stage I or II follicular lymphoma circulating t(14;18) positive cells could be detected in the peripheral blood.
  • In advanced stage follicular lymphoma patients molecular remissions could only be achieved when they were treated with combined chemo-immunotherapy (MCP+R).
  • In contrast, the frustrating clinical results obtained from the treatment of patients with mantle cell lymphoma corresponded to an achievement of only short molecular remissions in very few patients.
  • CONCLUSIONS: The consequent application of quantitative real-time PCR will further improve current treatment strategies in lymphoma patients.
  • [MeSH-major] Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / pathology. Neoplasm, Residual / diagnosis. Neoplastic Cells, Circulating. Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172952.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Masunaga A, Iwamoto S, Nakamura H, Usuda R, Masuda M, Suzuki S, Miyazaki A, Suzuki T, Mitsuya T, Yoshitake T: Thymic epithelial cells expressed unusual follicular dendritic cell markers: thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Pathol Int; 2008 Jun;58(6):402-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic epithelial cells expressed unusual follicular dendritic cell markers: thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
  • Described herein is a case of thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
  • Using immunohistochemical double staining it was found that most of the thymic lymphoid follicles in this case possessed cytokeratin-positive and follicular dendritic cell (FDC) marker-positive cells.
  • The present case indicates a possibility that some thymic epithelial cells become FDC, although it was uncertain whether they were derived from the epithelia of Hassall's corpuscles or whether they were at the same differentiation stage as Hassall's corpuscles.
  • [MeSH-major] Dendritic Cells, Follicular / metabolism. Lymphoma, B-Cell, Marginal Zone / metabolism. Thymus Gland / metabolism. Thymus Neoplasms / metabolism

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477221.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Complement 3d
  •  go-up   go-down


39. Abuzayed B, Dashti R, Turk O, Kaynar MY: Aneurysmal frontal bone cyst in a child with history of acute lymphoblastic leukemia: a case of rare location and history. J Pediatr Hematol Oncol; 2010 Jan;32(1):e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A preoperative diagnosis of myeloproliferative disorder was made and it was surgically resected and cranioplasty with porous polyethylene sheets (Medpor, Porex Surgical Inc, GA) was performed in the same stage.
  • [MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Bone Cysts, Aneurysmal / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636268.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Tisdale G, Mahadevan A, Matthews RH: T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion. Oncologist; 2005 Apr;10(4):292-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion.
  • Primary T-cell non-Hodgkin's lymphoma (NHL) occurring in the context of acquired immune deficiency syndrome (AIDS) is uncommon.
  • Although typical in some respects, the case is, in other ways, somewhat unusual for an AIDS-related NHL (ARL); ARL tends to be B cell and advanced stage and our case was T cell and stage IE.
  • Although this has largely been mitigated by the advent of highly active antiretroviral therapy, our patient eventually suffered complications of chemotherapy, apparently related more to his liver disease than to either his lymphoma or AIDS, that ultimately brought about his demise.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Hepatitis C / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Rectal Neoplasms / diagnosis


41. Ansell SM, Inwards DJ, Rowland KM Jr, Flynn PJ, Morton RF, Moore DF Jr, Kaufmann SH, Ghobrial I, Kurtin PJ, Maurer M, Allmer C, Witzig TE: Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer; 2008 Aug 1;113(3):508-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
  • BACKGROUND: The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL).
  • The median age was 69 years (range, 51-85 years), 86% of patients had stage IV disease, and 71% had > or = 2 extranodal sites.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • [Cites] Curr Treat Options Oncol. 2006 Jul;7(4):285-94 [16916489.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12 [16088404.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):116-21 [16971665.001]
  • [Cites] Leukemia. 2007 Feb;21(2):333-9 [17136116.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1299-306 [17613757.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4 [17875757.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1821-7 [15223642.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2269-71 [15166030.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • (PMID = 18543327.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA035267; United States / NCI NIH HHS / CA / CA112904; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / U10 CA060276; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / U10 CA035448; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-37403; United States / PHS HHS / / CS-35431; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / U10 CA035101; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / U10 CA035415; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / R21 CA112904; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / N01 CA015083
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS454018; NLM/ PMC3627208
  •  go-up   go-down


42. Saunders TS, Anis S, Doych Y, Moran A, Hou JS, Chen X, Yanoff M: Systemic non-Hodgkin's lymphoma involving the orbit and leptomeninges. Digit J Ophthalmol; 2010;16(3):9-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic non-Hodgkin's lymphoma involving the orbit and leptomeninges.
  • We report a case of diffuse large B-cell lymphoma in a 46-year-old female presenting in an unusual manner with stage IVB disease including concurrent orbital and leptomeningeal involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 2001 Jan;85(1):63-9 [11133714.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Jan;43(1):9-14 [11773006.001]
  • [Cites] Clin Experiment Ophthalmol. 2001 Dec;29(6):387-93 [11778809.001]
  • [Cites] Eye (Lond). 2003 Oct;17(7):809-20 [14528242.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Feb;242(2):130-45 [14685876.001]
  • [Cites] Ophthalmology. 2004 May;111(5):997-1008 [15121380.001]
  • [Cites] Cancer. 1985 May 1;55(9):1907-12 [3872159.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1449-52 [10329598.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2005 May;21(3):177-88 [15942490.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):597-609, v [16083825.001]
  • [Cites] Curr Opin Ophthalmol. 2006 Dec;17(6):523-31 [17065920.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]
  • [Cites] Arch Ophthalmol. 2007 Dec;125(12):1663-7 [18071119.001]
  • [Cites] Eye (Lond). 2010 Jun;24(6):954-61 [19942938.001]
  • (PMID = 23362375.001).
  • [Journal-full-title] Digital journal of ophthalmology : DJO
  • [ISO-abbreviation] Digit J Ophthalmol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3516149
  •  go-up   go-down


43. McNutt DM, Holdsworth MT, Wong C, Hanrahan JD, Winter SS: Rasburicase for the management of tumor lysis syndrome in neonates. Ann Pharmacother; 2006 Jul-Aug;40(7-8):1445-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient was a 21-day-old infant who received 2 days of induction chemotherapy for the treatment of congenital Stage IV-S neuroblastoma.
  • The second patient was a 4-day-old neonate with congenital precursor-B cell acute lymphoblastic leukemia who presented with spontaneous TLS complicated by renal dysfunction.
  • [MeSH-minor] Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / congenital. Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Humans. Infant, Newborn. Male. Neuroblastoma / blood. Neuroblastoma / complications. Neuroblastoma / congenital. Neuroblastoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Uric Acid / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868218.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  •  go-up   go-down


44. Golling P, Cozzio A, Dummer R, French L, Kempf W: Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. Leuk Lymphoma; 2008 Jun;49(6):1094-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome.
  • Clinical, prognostic and therapeutic features of 54 primary cutaneous marginal zone B-cell lymphoma (pcMZL), follicle centre lymphoma (pcFCL) and diffuse large B-cell lymphoma, leg type (pcDLBL) were analysed applying the WHO-EORTC classification for cutaneous lymphomas and the new TNM staging scheme of the International Society of Cutaneous Lymphomas.
  • Disseminated tumors (T3 stage) were found in 26% of patients with pcMZL and in one patient with pcDLBL.
  • Three of 7 patients (43%) with pcDLBL died due to lymphoma.
  • The new TNM staging system is easily applicable for disease documentation, but our relatively small number of patients in each T stage does not allow the assessment of its prognostic value.
  • [MeSH-major] Lymphoma, B-Cell / classification. Mycosis Fungoides / classification. Sezary Syndrome / classification. Skin Neoplasms / classification. World Health Organization
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / pathology. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis


45. Flory AB, Rassnick KM, Stokol T, Scrivani PV, Erb HN: Stage migration in dogs with lymphoma. J Vet Intern Med; 2007 Sep-Oct;21(5):1041-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage migration in dogs with lymphoma.
  • BACKGROUND: Various diagnostic tests have been used to assign a clinical stage to dogs with lymphoma.
  • As more sensitive staging methods are introduced, dogs are reclassified as having a higher disease stage, thereby affecting comparisons of dogs across differently staged clinical trials, and possibly, prognosis.
  • HYPOTHESIS: The addition of more sensitive staging tests causes stage migration in dogs with lymphoma.
  • ANIMALS: Fifty-nine client-owned dogs with previously untreated cytologically or histologically confirmed lymphoma METHODS: For every dog, the World Health Organization stage classification (I-V) was based on 5 groupings of various diagnostic tests: A (physical examination [PE] and quantitative blood count [QBC]), B (PE, QBC, thoracic and abdominal radiographs), C (PE, complete blood count with blood-smear evaluation [CBC], thoracic and abdominal radiographs), D (PE, CBC, thoracic radiographs, abdominal ultrasound), and E (PE, CBC, thoracic radiographs, abdominal ultrasound, and bone-marrow cytology).
  • However, the stage was not a predictor of remission rate, remission duration, or survival, regardless of staging method used.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: These data emphasized the need for standardized methods to determine the clinical stage in dogs with lymphoma.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939562.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


46. Shen Y, Yao Y, Li JM, Chen QS, You JH, Zhao HJ, Chen S, Shen ZX: [Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2008 Apr;29(4):252-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
  • OBJECTIVE: To reassess the prognostic factors of diffuse large B cell lymphoma (DLBCL) treated with R-CHOP therapy.
  • In univariate analysis, performance status (PS), clinical stage, LDH level, extranodal disease, international prognostic index (IPI) and bulky disease were statistically significantly correlated with the induction of CR; however, only PS, clinical stage and bulky disease remained significant in multi-variate analysis (P = 0.0098, 0.000 and 0.004, respectively).
  • In univariate analysis, LDH, clinical stage and PS exerted significant effect on TTF and OS rate, but not on DFS rate; age and extranodal disease was not related with TTF, OS and DFS rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843980.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


47. Attarbaschi A, Dworzak M, Steiner M, Urban C, Fink FM, Reiter A, Gadner H, Mann G: Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer; 2005 Jan;44(1):70-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
  • BACKGROUND: Children and adolescents with Non-Hodgkin lymphoma (NHL) and mature B-cell leukemia (B-ALL) have an excellent prognosis with contemporary chemotherapy stratified according to the histologic subtype and clinical stage of disease.
  • RESULTS: Nine of 140 (6.5%) patients with B-cell NHL/B-ALL (relapse, n = 6; progress, n = 3) failed initial treatment.
  • Four of them underwent a hematopoietic stem cell transplantation (HSCT) as second-line therapy, two patients received intensive chemotherapy alone and in three patients treatment was palliative.
  • Four of 65 (6%) patients with lymphoblastic lymphoma (LBL) (relapse, n = 2; progress, n = 2) had a treatment failure.
  • Nine of 29 (31%) patients with anaplastic large cell lymphoma (ALCL) (relapse, n = 7; progress, n = 2) failed first-line therapy.
  • CONCLUSIONS: Conclusively, patients with early relapsed and progressive B-cell neoplasia or LBL have a very poor prognosis with current treatment approaches, while those with ALCL have a respectable chance to achieve a sustained complete second remission with high-dose chemotherapy and HSCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15368550.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


48. Laport GG: The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2006 Jan;12(1 Suppl 1):59-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma.
  • The overall survival with follicular lymphoma has not significantly changed over the last few decades, and there is no universal agreement as to the optimal first-line or subsequent therapy.
  • High-dose chemotherapy with autologous hematopoietic cell transplantation (HCT) confers high response rates and improved progression-free survival in advanced-stage disease, and more recent data indicate a positive effect on overall survival.
  • This review summarizes current and new developments regarding the role of HCT for patients with follicular lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Follicular / therapy. Transplantation Conditioning

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399587.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunoconjugates; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 36
  •  go-up   go-down


49. Ishikawa M, Kitayama J, Nagawa H: Expression pattern of leptin and leptin receptor (OB-R) in human gastric cancer. World J Gastroenterol; 2006 Sep 14;12(34):5517-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression levels of both leptin and OB-R tended to increase as the depth of tumor invasion or TMN stage increased (P < 0.01).
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Signet Ring Cell / metabolism. Leptin / metabolism. Receptors, Cell Surface / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Horm Metab Res. 2001 Jan;33(1):1-6 [11280707.001]
  • [Cites] Surgery. 1970 Jul;68(1):209-16 [10483471.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):79-90 [11438496.001]
  • [Cites] Cytokine. 2001 May 21;14(4):225-9 [11448122.001]
  • [Cites] Gut. 2001 Sep;49(3):324-9 [11511551.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S94-100 [12570341.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Apr;105(2):111-6 [12691803.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):592-600 [12894247.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):581-4 [15033662.001]
  • [Cites] Cancer Res. 1981 Sep;41(9 Pt 2):3685-90 [6266659.001]
  • [Cites] Fertil Steril. 2000 Mar;73(3):493-8 [10689001.001]
  • [Cites] Leuk Lymphoma. 2000 Feb;36(5-6):457-61 [10784389.001]
  • [Cites] Mol Cell Endocrinol. 2000 Jul 25;165(1-2):97-105 [10940488.001]
  • [Cites] Gut. 2000 Oct;47(4):481-6 [10986207.001]
  • [Cites] FASEB J. 2000 Nov;14(14):2329-38 [11053255.001]
  • [Cites] Biol Reprod. 2000 Nov;63(5):1219-28 [11058523.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):421-30 [11169969.001]
  • [Cites] Cancer Res. 1981 Sep;41(9 Pt 2):3695-9 [7260926.001]
  • [Cites] Cancer Res. 1988 Jun 15;48(12):3518-23 [3370645.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] Diabetes. 1996 May;45(5):695-8 [8621026.001]
  • [Cites] Nature. 1996 Apr 25;380(6576):677 [8614460.001]
  • [Cites] Nat Med. 1996 May;2(5):585-9 [8616721.001]
  • [Cites] Diabetes. 1996 Nov;45(11):1455-62 [8866547.001]
  • [Cites] Diabetes. 1997 Feb;46(2):313-6 [9000710.001]
  • [Cites] J Nutr. 1997 May;127(5 Suppl):921S-923S [9164264.001]
  • [Cites] Proc Soc Exp Biol Med. 1997 Oct;216(1):28-43 [9316608.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11073-8 [9380761.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cell. 1998 Feb 20;92(4):437-40 [9491885.001]
  • [Cites] Int J Epidemiol. 1998 Apr;27(2):173-80 [9602395.001]
  • [Cites] Nature. 1998 Aug 20;394(6695):790-3 [9723619.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56 [9752982.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Dec;83(12):4459-66 [9851794.001]
  • [Cites] Lipids. 1998 Nov;33(11):1055-9 [9870899.001]
  • [Cites] Eur J Pharmacol. 1999 Jan 22;365(2-3):273-9 [9988112.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Nutrition. 1999 Jun;15(6):523-6 [10378216.001]
  • [Cites] Eur J Pharmacol. 1999 Jun 18;374(2):263-76 [10422768.001]
  • [Cites] Nature. 2001 May 17;411(6835):390-5 [11357148.001]
  • (PMID = 17006991.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human
  • [Other-IDs] NLM/ PMC4088236
  •  go-up   go-down


50. Ria R, Cirulli T, Giannini T, Bambace S, Serio G, Portaluri M, Ribatti D, Vacca A, Dammacco F: Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. Clin Exp Med; 2008 Sep;8(3):141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas.
  • Herein, we set out to determine whether circulating fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and platelet-derived growth factor-beta (PDGF-beta) decrease after radiotherapy in patients with non-Hodgkin lymphomas (NHLs) and if so, whether their decrease correlates with age, tumour histotype and stage, and radiation dose.
  • These levels were correlated both reciprocally and with age, histotype, stage and radiation dose.
  • Haemoglobin levels did not decrease after radiotherapy, while FGF-2, VEGF, HGF and PDGF-beta levels did not correlate with age, NHL stage and histotype.
  • [MeSH-major] Cytokines / blood. Lymphoma, Non-Hodgkin / radiotherapy. Neovascularization, Pathologic

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1207-25 [11181687.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1359-64 [10581076.001]
  • [Cites] Nat Med. 2001 May;7(5):575-83 [11329059.001]
  • [Cites] Radiother Oncol. 2003 Jan;66(1):1-9 [12559515.001]
  • [Cites] Head Neck. 2000 Oct;22(7):666-73 [11002321.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67 [17828470.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7508-16 [17563752.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):536-42 [11740806.001]
  • [Cites] Eur Cytokine Netw. 2003 Jan-Mar;14(1):40-51 [12799213.001]
  • [Cites] Cancer Lett. 2002 May 28;179(2):197-203 [11888674.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):514-21 [11736931.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C947-70 [11940508.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Breast Cancer Res. 2003;5(2):83-8 [12631386.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):690-8 [11745464.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3344-51 [12384436.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):41-8 [18097541.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4033-42 [17827451.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8980-4 [17908997.001]
  • [Cites] Int J Cancer. 2002 Sep 1;101(1):86-94 [12209593.001]
  • [Cites] Cancer Lett. 2004 Dec 8;216(1):103-7 [15500953.001]
  • [Cites] Hormones (Athens). 2006 Apr-Jun;5(2):137-46 [16807226.001]
  • (PMID = 18791686.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


51. Ulmeanu R, Mihăltan F, Crişan E, Alexe M, Grigore P, Andreescu I, Galbenu P, Leonte D: [Practical issues of transbronchial lung biopsy (TLB) in pneumology]. Pneumologia; 2007 Apr-Jun;56(2):59-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of lung pathology was: diffuse lung fibrosis, tuberculosis, sarcoidosis stage II-III, malignant lymphoma, carcinomatosis, undifferentiated carcinoma, bronchioloalveolar carcinoma, squamous carcinoma, adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Granulomatosis with Polyangiitis / pathology. Health Surveys. Humans. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Practice Guidelines as Topic. Pulmonary Fibrosis / pathology. Sarcoidosis, Pulmonary / pathology. Sensitivity and Specificity. Tuberculosis, Pulmonary / pathology

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019749.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


52. Lam J, Pope E: Pediatric pityriasis lichenoides and cutaneous T-cell lymphoma. Curr Opin Pediatr; 2007 Aug;19(4):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric pityriasis lichenoides and cutaneous T-cell lymphoma.
  • PURPOSE OF REVIEW: The purpose of this review is to educate the reader about two cutaneous lymphoproliferative diseases in childhood: pityriasis lichenoides and cutaneous T-cell lymphoma.
  • Cutaneous T-cell lymphoma is a rare but underrecognized cutaneous malignancy in children.
  • Early stage disease and hypopigmented presentation are characteristic of pediatric cutaneous T-cell lymphoma.
  • RECENT FINDINGS: This article will summarize recent articles on pityriasis lichenoides and pediatric cutaneous T-cell lymphoma, including recent findings from an international registry of pediatric cutaneous T-cell lymphoma.
  • SUMMARY: After reading this review, the reader should be able to recognize the clinical presentation of pityriasis lichenoides, to understand the overlap between its acute and chronic forms, and to recognize its relationship with cutaneous T-cell lymphoma.
  • In addition, the reader will appreciate the challenges in diagnosing and treating pediatric cutaneous T-cell lymphoma.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / diagnosis. Pityriasis Lichenoides / diagnosis. Skin Neoplasms / diagnosis


53. Valli VE, Vernau W, de Lorimier LP, Graham PS, Moore PF: Canine indolent nodular lymphoma. Vet Pathol; 2006 May;43(3):241-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine indolent nodular lymphoma.
  • B-Cell lymphomas (CD79a+) predominated.
  • Marginal zone lymphoma (MZL), the largest group, involved lymph node (33 cases) and spleen (13 cases), with both tissues involved in five of these cases.
  • Follicular lymphoma (FL) involved lymph nodes (five cases), and mantle cell lymphoma (MCL) occurred as solitary splenic masses (three cases).
  • Nodal CD3+ T-zone lymphomas (TZL) (10 cases), were included since they resembled late-stage MZL at the architectural level.
  • Clonality status was determined in 54 cases by analysis of immunoglobulin heavy chain (IGH) and T-cell antigen receptor gamma (TCRG) gene rearrangement.
  • Limited survival data obtained for 18 dogs indicated that the B-cell lymphomas (MZL, MCL, and FL) and the T-cell lymphoma (TZL) were associated with indolent behavior and long survival.
  • [MeSH-major] Dog Diseases / diagnosis. Lymphoma, Follicular / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Dogs. Female. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / pathology. Lymphoma, Mantle-Cell / veterinary. Male. Splenic Neoplasms / diagnosis. Splenic Neoplasms / drug therapy. Splenic Neoplasms / pathology. Splenic Neoplasms / veterinary

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672571.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


54. Wang H, Li XJ, Zhang SW, Xi Y: [Clinical study of extranodal NK-T cell lymphoma-nasal type]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Nov;40(11):850-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of extranodal NK-T cell lymphoma-nasal type].
  • OBJECTIVE: To discuss how the diagnosis, misdiagnosis and different treatment modalities affect the prognosis of the patients with extranodal NK-T cell lymphoma-nasal type.
  • METHODS: A retrospective study was made on the clinical characteristics, treatment modality, short-term effect, and survival rate of 68 patients with extranodal NK-T cell lymphoma-nasal type.
  • CONCLUSIONS: The early clinical manifestation of extranodal NK-T cell lymphoma-nasal type is not typical,which is easy to be misdiagnosed and mistreated.
  • Diseased stage I(E) out-cavity and above should be treated with combined therapy.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell. Nose Neoplasms

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408753.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


55. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol; 2005 Dec;16(12):1928-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
  • BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia.
  • Group A (resected stage I and abdominal stage II disease) received three courses of vincristine, cyclophosphamide, doxorubicin and prednisone.
  • CONCLUSION: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Behler CM, Kaplan LD: Advances in the management of HIV-related non-Hodgkin lymphoma. Curr Opin Oncol; 2006 Sep;18(5):437-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of HIV-related non-Hodgkin lymphoma.
  • PURPOSE OF REVIEW: Human immunodeficiency virus infection is associated with an increased risk of non-Hodgkin lymphoma.
  • Even with a decrease in AIDS-defining illnesses after the advent of highly active antiretroviral therapy, HIV-associated non-Hodgkin lymphoma remains an important problem.
  • RECENT FINDINGS: Low CD4+ T-lymphocyte count, disease stage, performance status, serum lactate dehydrogenase, and number of extranodal sites of disease are all important prognostic factors for HIV-non-Hodgkin lymphoma.
  • Recent studies have examined the role of infusional chemotherapy, as well as immunotherapy, in the treatment of aggressive HIV-non-Hodgkin lymphoma, and autologous stem cell transplantation for relapsed or refractory HIV-non-Hodgkin lymphoma.
  • New developments in the association of viral infection and pathogenesis of certain subtypes of HIV-non-Hodgkin lymphoma have also recently been reported.
  • SUMMARY: Outcomes of HIV-non-Hodgkin lymphoma are improving with the routine use of highly active antiretroviral therapy and combination chemotherapy.
  • For aggressive HIV-non-Hodgkin lymphoma, infusional chemotherapy regimens are well tolerated and lead to complete response in about 50-75% of cases and a 2-3 years overall survival of 40-60%.
  • HIV-associated Burkitt lymphoma should be treated with an intensive regimen rather than standard cyclophosphamide, doxorubicin, vincristine, prednisone-like chemotherapy.
  • Autologous stem cell transplantation should be considered for selected patients with relapsed or refractory HIV-non-Hodgkin lymphoma.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894290.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 65
  •  go-up   go-down


57. Takino H, Okabe M, Li C, Ohshima K, Yoshino T, Nakamura S, Ueda R, Eimoto T, Inagaki H: p16/INK4a gene methylation is a frequent finding in pulmonary MALT lymphomas at diagnosis. Mod Pathol; 2005 Sep;18(9):1187-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, their significance in mucosa-associated lymphoid tissue (MALT) lymphoma is unclear.
  • We investigated p16 gene methylation and mutation in a large series of untreated cases of pulmonary MALT lymphoma and diffuse large B-cell lymphoma (DLBL), and correlated p16 gene alterations with a MALT lymphoma-specific API2-MALT1 fusion and the clinicopathologic features of MALT lymphoma.
  • The API2-MALT1 fusion was detected by multiplex reverse transcription polymerase chain reaction in 25/60 (42%) cases of MALT lymphoma, but none of 11 DLBLs.
  • Methylation-sensitive single-strand conformation analysis showed that p16 gene methylation was frequently detected in 36/60 (60%) cases of MALT lymphoma.
  • A p16 gene mutation was found in one (p16 gene-methylation) of 44 MALT lymphomas and in none of six diffuse large B-cell lymphomas.
  • Statistical analysis showed that the p16 gene methylation status did not correlate with API2-MALT1 fusion or any of the clinicopathologic factors including serum LDH, clinical stage, and increased large cells.
  • [MeSH-major] DNA Methylation. Genes, p16. Lung Neoplasms / genetics. Lymphoma, B-Cell, Marginal Zone / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Male. Middle Aged. Mutation. Oncogene Proteins, Fusion / genetics. Polymorphism, Single-Stranded Conformational. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832193.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


58. Huang AC, Hu L, Kauffman SA, Zhang W, Shmulevich I: Using cell fate attractors to uncover transcriptional regulation of HL60 neutrophil differentiation. BMC Syst Biol; 2009;3:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using cell fate attractors to uncover transcriptional regulation of HL60 neutrophil differentiation.
  • BACKGROUND: The process of cellular differentiation is governed by complex dynamical biomolecular networks consisting of a multitude of genes and their products acting in concert to determine a particular cell fate.
  • Thus, a systems level view is necessary for understanding how a cell coordinates this process and for developing effective therapeutic strategies to treat diseases, such as cancer, in which differentiation plays a significant role.
  • Theoretical considerations and recent experimental evidence support the view that cell fates are high dimensional attractor states of the underlying molecular networks.
  • The temporal behavior of the network states progressing toward different cell fate attractors has the potential to elucidate the underlying molecular mechanisms governing differentiation.
  • RESULTS: Using the HL60 multipotent promyelocytic leukemia cell line, we performed experiments that ultimately led to two different cell fate attractors by two treatments of varying dosage and duration of the differentiation agent all-trans-retinoic acid (ATRA).
  • The dosage and duration combinations of the two treatments were chosen by means of flow cytometric measurements of CD11b, a well-known early differentiation marker, such that they generated two intermediate populations that were poised at the apparently same stage of differentiation.
  • We monitored the gene expression changes in the two populations after their respective treatments over a period of five days and identified a set of genes that diverged in their expression, a subset of which promotes neutrophil differentiation while the other represses cell cycle progression.
  • By employing promoter based transcription factor binding site analysis, we found enrichment in the set of divergent genes, of transcription factors functionally linked to tumor progression, cell cycle, and development.
  • [MeSH-major] Cell Differentiation / physiology. Gene Expression Regulation / physiology. Neutrophils / cytology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Jun 2;281(22):15138-44 [16574653.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1326-9 [16688227.001]
  • [Cites] J Neuroendocrinol. 2006 Sep;18(9):633-42 [16879162.001]
  • [Cites] Dev Biol. 2006 Oct 15;298(2):555-70 [16949568.001]
  • [Cites] J Biol Chem. 2007 Jan 5;282(1):208-15 [17062569.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D610-7 [17148474.001]
  • [Cites] Leukemia. 2007 Feb;21(2):288-96 [17183364.001]
  • [Cites] Cell Cycle. 2007 Mar 15;6(6):714-24 [17361102.001]
  • [Cites] J Theor Biol. 2007 May 21;246(2):234-44 [17289080.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C172-83 [17360815.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2302-11 [17569791.001]
  • [Cites] Curr Top Dev Biol. 2008;81:311-40 [18023733.001]
  • [Cites] FASEB J. 2007 Dec;21(14):4059-69 [17675532.001]
  • [Cites] Cell. 2007 Dec 28;131(7):1354-65 [18160043.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1686-93 [18209065.001]
  • [Cites] J Neurosci. 2008 Feb 6;28(6):1410-20 [18256261.001]
  • [Cites] BMC Bioinformatics. 2007;8:462 [18039375.001]
  • [Cites] PLoS Comput Biol. 2008 Mar;4(3):e1000021 [18369420.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):289-91 [18394549.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):299-310 [18394553.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):372-9 [18362948.001]
  • [Cites] Mol Cell. 2008 May 9;30(3):290-302 [18471975.001]
  • [Cites] Nature. 2008 May 22;453(7194):544-7 [18497826.001]
  • [Cites] Environ Health Perspect. 1993 Dec;101 Suppl 5:15-26 [7516873.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1131-8 [7518549.001]
  • [Cites] Proc Soc Exp Biol Med. 1995 Jan;208(1):109-15 [7892284.001]
  • [Cites] Biosci Rep. 1994 Dec;14(6):259-81 [7620078.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] Nucleic Acids Res. 1996 Jan 1;24(1):238-41 [8594589.001]
  • [Cites] Exp Cell Res. 1996 Mar 15;223(2):290-300 [8601406.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12359-63 [8901586.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] J Neurosci Res. 2000 Aug 15;61(4):364-70 [10931522.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5711-9 [11060022.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):91-103 [11082279.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):224-34 [11113197.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):263-70 [11242107.001]
  • [Cites] Nat Med. 2001 Apr;7(4):444-51 [11283671.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Exp Cell Res. 2001 May 15;266(1):126-34 [11339831.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):706-14 [11698186.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13120-5 [11687616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):757-62 [11805330.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1364-72 [11830488.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1723-32 [11927556.001]
  • [Cites] Genome Res. 2002 Jun;12(6):996-1006 [12045153.001]
  • [Cites] Genes Dev. 2002 Jul 15;16(14):1760-5 [12130536.001]
  • [Cites] Bioinformatics. 2002 Oct;18(10):1319-31 [12376376.001]
  • [Cites] Haematologica. 2002 Dec;87(12):1307-23 [12495904.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7 [12552125.001]
  • [Cites] Biochem Pharmacol. 2003 Mar 1;65(5):813-21 [12628493.001]
  • [Cites] Front Biosci. 2003 May 1;8:s206-22 [12700034.001]
  • [Cites] Genome Biol. 2003;4(4):R28 [12702209.001]
  • [Cites] Immunobiology. 2003;207(3):217-21 [12777063.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):8934-45 [14645506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14875-80 [14657364.001]
  • [Cites] Immunobiology. 2003;208(4):391-9 [14748512.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):65-75 [14965268.001]
  • [Cites] Bioinformatics. 2004 Apr 12;20(6):924-30 [14751971.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1231-7 [15103390.001]
  • [Cites] Curr Biol. 2004 Oct 5;14(19):1712-22 [15458642.001]
  • [Cites] J Theor Biol. 1969 Mar;22(3):437-67 [5803332.001]
  • [Cites] Proc Natl Acad Sci U S A. 1970 Jun;66(2):352-9 [5271168.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 May;75(5):2458-62 [276884.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Jun;76(6):2779-83 [288066.001]
  • [Cites] Blood. 1979 Sep;54(3):713-33 [288488.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40 [6930676.001]
  • [Cites] Leuk Res. 1983;7(1):51-5 [6682163.001]
  • [Cites] J Cell Physiol. 1984 Mar;118(3):277-86 [6583206.001]
  • [Cites] Exp Cell Res. 1984 Jun;152(2):493-9 [6586426.001]
  • [Cites] Leuk Res. 1985;9(1):51-71 [3857406.001]
  • [Cites] Blood. 1986 Jan;67(1):31-6 [3484427.001]
  • [Cites] J Cell Sci Suppl. 1989;12:21-7 [2699735.001]
  • [Cites] EMBO J. 1990 Oct;9(10):3343-51 [2209547.001]
  • [Cites] Genomics. 1992 Jul;13(3):565-74 [1386335.001]
  • [Cites] Cell. 1993 May 7;73(3):487-97 [8343202.001]
  • [Cites] Leuk Lymphoma. 1993 Nov;11(5-6):331-8 [8124204.001]
  • [Cites] Science. 1994 May 27;264(5163):1326-9 [8191287.001]
  • [Cites] Bull Math Biol. 1997 Jan;59(1):139-96 [8980305.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):195-202 [9010221.001]
  • [Cites] Mol Biol Cell. 1999 Mar;10(3):785-98 [10069818.001]
  • [Cites] Blood. 1999 May 1;93(9):2760-70 [10216069.001]
  • [Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5468-74 [15590664.001]
  • [Cites] J Theor Biol. 2005 May 21;234(2):173-86 [15757677.001]
  • [Cites] Curr Opin Hematol. 2005 May;12(3):210-6 [15867577.001]
  • [Cites] Phys Rev Lett. 2005 Apr 1;94(12):128701 [15903968.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):175-6 [16169461.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2241-6 [16239915.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):228-33 [16380711.001]
  • [Cites] BMC Cell Biol. 2006;7:11 [16507101.001]
  • [Cites] Biosystems. 2006 May;84(2):101-14 [16386358.001]
  • [Cites] Nature. 2006 May 11;441(7090):173-8 [16688168.001]
  • (PMID = 19222862.001).
  • [ISSN] 1752-0509
  • [Journal-full-title] BMC systems biology
  • [ISO-abbreviation] BMC Syst Biol
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / P50 GM076547; United States / NIGMS NIH HHS / GM / P50 GM076547; United States / NIGMS NIH HHS / GM / R01 GM072855; United States / NIGMS NIH HHS / GM / R21 GM070600
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD11b; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ PMC2652435
  •  go-up   go-down


59. Chin KM, Foss FM: Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox. Clin Lymphoma Myeloma; 2006 Nov;7(3):199-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
  • BACKGROUND: Denileukin diftitox, a fusion protein consisting of peptide sequences for the enzymatically active and membrane translocation domains of diphtheria toxin and human interleukin, resulted in a response rate of 30% in the phase III registration trial in patients with recurrent or persistent cutaneous T-cell lymphoma (CTCL).
  • PATIENTS AND METHODS: In our single-center series of 37 patients with early- and advanced-stage disease with CTCL treated with denileukin diftitox at a dose of 9 microg/kg or 18 microg/kg per day, we observed an overall response rate of 51%.
  • RESULTS: In 8 patients with early-stage (< IIA) CTCL, there were 5 responses (62.5%), and the median survival has not been reached, with 70% of patients still alive at 46 months.
  • In 29 patients with advanced-stage (>/= IIB) disease, there were 14 responses (49.3%), and the median survival was 31 months.
  • Changes in the number of CD4+ CD25+ T-cell populations were observed in 7 of 19 responders, with no overall changes in the absolute lymphocyte counts during the course of therapy.
  • CONCLUSION: Denilekin diftitox was a well-tolerated treatment in early- and advanced-stage CTCL and was not associated with detrimental immunologic efects on lymphocyte populations.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Lymphoma, T-Cell, Cutaneous / mortality. Skin Neoplasms / drug therapy. Skin Neoplasms / mortality

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229335.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


60. Shen L, Suresh L, Li H, Zhang C, Kumar V, Pankewycz O, Ambrus JL Jr: IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans. Clin Immunol; 2009 Mar;130(3):304-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transgenic mice in which IL-14a expression was increased constitutively were previously demonstrated to develop hypergammaglobulinemia, autoantibodies, infiltration of the parotid glands with lymphocytes, mild immune-complex mediated renal disease and large B cell lymphoma.
  • In this paper we expand these observations to demonstrate that these mice develop all the clinical and immunological features of primary Sjögren's disease in the same relative time frame as patients with primary Sjögren's disease: stage 1-early hypergammaglobulinemia and autoantibody production, stage 2-decreased salivary gland function with early lymphocytic infiltration of the submandibular glands only, but antibody deposition in the submandibular and parotid glands, stage 3-lymphocytic infiltration of the submandibular, parotid and lacrimal glands with B and T lymphocytes and plasma cells along with interstitial lung disease and mild renal disease, and stage 4-large B cell lymphoma.


61. Kim JH, Lee JH, Lee J, Oh SO, Chang DK, Rhee PL, Kim JJ, Rhee JC, Lee J, Kim WS, Ko YH: Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings. Endoscopy; 2007 Feb;39(2):156-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings.
  • BACKGROUND AND STUDY AIMS: Primary NK-/T-cell lymphoma of the gastrointestinal tract is a very rare disease with a poor prognosis.
  • The aim of this study was to determine the clinical and endoscopic characteristics of patients with primary gastrointestinal NK-/T-cell lymphoma.
  • PATIENTS AND METHODS: The clinical features of 14 patients with primary gastrointestinal NK-/T-cell lymphoma and the endoscopic findings in 11 of these patients were reviewed.
  • RESULTS: The initial presenting symptoms of primary gastrointestinal NK-/T-cell lymphoma were gastrointestinal bleeding (n = 6, 42%), abdominal pain (n = 4, 29%), and epigastric soreness (n = 4, 29%).
  • The disease was at an advanced stage at the time of diagnosis: stage II in 5 patients (36%); stage III in 4 (28%); and stage IV in 5 (36%).
  • CONCLUSIONS: Primary gastrointestinal NK-/T-cell lymphoma was endoscopically characterized by superficial/erosive, ulcerative, or ulceroinfiltrative lesions without fungating mass.
  • [MeSH-major] Endoscopy, Gastrointestinal. Gastrointestinal Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657701.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D, Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute: Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica; 2010 Oct;95(10):1705-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: This study demonstrates the role of biomarkers in prognosis and shows that, in patients requiring treatment, disease stage may no longer be an independent predictor of outcome.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / pathology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2009 Jun;145(6):801-5 [19388937.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1637-43 [19224852.001]
  • [Cites] Br J Haematol. 2009 Jun;146(1):44-53 [19438486.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2262-4 [11877310.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):105-11 [14726163.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Haematologica. 2005 Apr;90(4):465-9 [15820941.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2124-32 [16211545.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):437-43 [16344317.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2889-94 [16317103.001]
  • [Cites] Blood. 2007 Jan 1;109(1):259-70 [16985177.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3352-9 [17684154.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4012-21 [17699742.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1524-33 [17959859.001]
  • [Cites] Blood. 2008 May 15;111(10):5173-81 [18326821.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3322-9 [18689542.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2108-15 [19021053.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):373-80 [19117034.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):995-1004 [19188171.001]
  • (PMID = 20511662.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN58585610; ClinicalTrials.gov/ NCT00004218
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2948096
  • [Investigator] Bloor A; Nathwani A; Duncombe A; Pettitt A; Schuh A; Kennedy B; Pepper C; Fegan C; Pocock C; Dearden C; Catovsky D; Oscier D; Cohen D; Matutes E; Follows G; Gribben J; Leach M; Else M; Fenwick N; Hillmen P; Wade R; Marshall S; Devereux S; Richards S; Hambin T; Gregory W
  •  go-up   go-down


63. Tanţău M, Tanţău A, Zaharia T, Cucuianu A: Gastrointestinal lymphomatous polyposis--clinical, endoscopical and evolution features. A case report. Rom J Gastroenterol; 2005 Sep;14(3):273-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary gastrointestinal non-Hodgkin lymphoma accounts for 13-18% of all malignant tumours of small bowel and only 1 % of large bowel tumours (1).
  • Majority of cases with gastrointestinal primary lymphoma are classified histologically as "mantle cell" lymphomas.
  • Histopathological and immunohistochemical studies on biopsy specimens from colon and duodenum confirmed gastrointestinal non-Hodgkin lymphoma, probably "mantle cell" lymphoma.
  • Because she was in an advanced stage she received only cytostatic treatment.
  • [MeSH-major] Intestinal Polyps / pathology. Lymphoma, Mantle-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200239.001).
  • [ISSN] 1221-4167
  • [Journal-full-title] Romanian journal of gastroenterology
  • [ISO-abbreviation] Rom J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


64. Wada N, Ikeda J, Kohara M, Ogawa H, Hino M, Fukuhara S, Kanamaru A, Sugiyama H, Kanakura Y, Morii E, Aozasa K: Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group. Virchows Arch; 2009 Sep;455(3):285-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group.
  • The aim of this study was to clarify whether diffuse large B-cell lymphoma (DLBCL) with a high number of epithelioid histiocytes (DLBCL-EH) could have distinctive clinicopathological characteristics.
  • Stage of disease was I in five cases, II in three, III in nine, and IV in five.
  • [MeSH-major] Histiocytes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1764-73 [17786712.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):229-36 [14687617.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Histopathology. 2002 Jan;40(1):31-45 [11903596.001]
  • [Cites] Pediatr Blood Cancer. 2008 Oct;51(4):557-9 [18523988.001]
  • [Cites] Am J Surg Pathol. 1992 Apr;16(4):351-63 [1373580.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] J Clin Exp Hematop. 2007 Apr;47(1):23-6 [17510535.001]
  • [Cites] Eur J Haematol. 2007 Dec;79(6):501-7 [17986209.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1271-7 [12663714.001]
  • [Cites] Cancer. 1978 Feb;41(2):562-7 [630538.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):65-75 [7817948.001]
  • [Cites] Oncologist. 2006 Apr;11(4):384-92 [16614234.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • (PMID = 19727807.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


65. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES: Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol; 2010 Jul;23(7):991-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.
  • Plasmablastic lymphoma, which is considered a subtype of diffuse large B-cell lymphoma, shares many similar morphological and immunophenotypic features with plasmablastic transformation of plasma cell myeloma.
  • We report four unique cases of plasmablastic lymphoma occurring in the setting of HIV infection that had overlapping clinical and genetic features with plasma cell myeloma.
  • In addition to extra-nodal disease, plasmablastic morphology, and phenotype typical of plasmablastic lymphoma, three of the four cases also showed clinical findings overlapping with plasma cell myeloma, that is, monoclonal serum immunoglobulin and lytic bone lesions.
  • Furthermore, these cases showed complex cytogenetic changes that are more commonly observed in plasma cell myeloma.
  • MYC translocation has been associated with tumor progression in multiple myeloma but has only rarely been previously reported in plasmablastic lymphoma.
  • These cases show a clinical and biological relationship between plasmablastic lymphoma and the plasmablastic variant of plasma cell myeloma.
  • Dysregulation of MYC may be a common genetic mechanism that imparts plasmablastic morphology and aggressive clinical course to B-cell neoplasms at a later stage of differentiation.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Multiple Myeloma / genetics. Multiple Myeloma / pathology. Proto-Oncogene Proteins c-myc / genetics

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348882.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


66. Kneile JR, Tan G, Suster S, Wakely PE Jr: Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma. Histopathology; 2006 Jun;48(7):855-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma.
  • AIMS: Undifferentiated nasopharyngeal non-keratinizing carcinoma (UNPC), formerly known as lymphoepithelioma, frequently metastasizes at an early stage to regional lymph nodes and, thus, may be difficult to distinguish from Hodgkin's lymphoma (HL) or anaplastic large cell lymphoma (ALCL).
  • The aim of this study was to evaluate CD30 expression in UNPC and lymphoepithelioma-like carcinoma (LELC) from other anatomic locations and compare it with ALCL and squamous cell carcinoma (SCC).
  • [MeSH-major] Antigens, CD30 / biosynthesis. Carcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Nasopharyngeal Neoplasms / pathology


67. Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougenot B, Roudot-Thoraval F, Vanhille P, Moranne O, Hachulla E, Hatron PY, Fermand JP, Fakhouri F, Ronco P, Plaisier E, Grimbert P: Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore); 2009 Nov;88(6):341-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MC was related to primary Sjögren Syndrome (pSS) in 9 patients, and to non-Hodgkin lymphoma in 1 patient, while MC was classified as essential in the remaining 10 cases.
  • However, renal relapse occurred in most patients, with 10% reaching end-stage renal disease.
  • Three patients with essential MC developed B-cell lymphoma 36-48 months after the diagnosis of MC.
  • Unexpectedly, B-cell lymphoma induced by Epstein-Barr virus infection occurred in only 1 of the 9 pSS patients.
  • Forty percent of patients died as a result of extrarenal causes.Renal disease associated with MC unrelated to HCV is characterized by the high prevalence of pSS (45%), the finding of CD20+ B-lymphocyte nodular infiltrates in the kidney interstitium, and a high incidence of overt B-cell lymphoma during follow-up.

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910748.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


68. Feng LJ, Zhang GP, Xie M, Cao PF, Fu CY, Hu ZL, Dai M: [Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jul;11(7):555-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma].
  • OBJECTIVE: Some research has shown that primary intestinal lymphoma with the same immunophenotype has different prognosis.
  • This study aimed to explore the role of the p53 gene and chromosome 13q14 variations in the assessment of prognosis in primary intestinal lymphoma.
  • METHODS: p53 gene and chromosome 13q14 expression in paraffin sections of 30 cases of primary intestinal lymphoma and 10 cases of lymph node reactive hyperplasia were ascertained using an improved FISH technique.
  • RESULTS: p53 gene deletion was found in 22.7% of patients with primary intestinal lymphoma at stage I-II and in 75.0% of patients at stage III-IV (x2=6.903, p<0.01).
  • The 30 patients with primary intestinal lymphoma were pathologically classified into-mucosa-associated lymphoid tissue (MALT) (n=14) and non-MALT types (n=16).
  • The MALT lymphoma group had significantly lower incidence of p53 gene deletion (14.3% vs 56.3%; x2=5.662, p<0.05).
  • 13q14 deletion was found in 40.0% of patients with primary intestinal lymphoma, but none of patients with lymph node reactive hyperplasia showed 13q14 deletion.
  • 13q14 deletion was not significantly related to the pathological type and the clinical stage of primary intestinal lymphoma as well as the survival time.
  • CONCLUSIONS: There was a high incidence of p53 gene deletion in patients with non-MALT lymphoma or at stage III-IV. p53 gene deletion is related to a high tumor malignant degree and a poor prognosis, while-chromosome 13q14 variation is not associated with the prognosis in patients with primary intestinal lymphoma.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 13. Genes, p53. Intestinal Neoplasms / genetics. Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Humans. In Situ Hybridization, Fluorescence. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / mortality. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650989.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS: Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma; 2010 Jul;51(7):1217-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience.
  • The purpose of this study was to assess the clinicopathologic characteristics and outcomes in patients with diffuse large B-cell lymphoma (DLBCL) of the testis, and to assess the impact of changes in the therapeutic approach that have occurred over the years.
  • Factors analyzed included: age, clinical stage, B-symptoms, serum levels of lactate dehydrogenase (LDH), beta(2)-microglobulin, treatment received, and outcome.
  • Immunophenotypic data were available for 43 cases, all of which showed B-cell lineage.
  • Advanced stage, elevated serum LDH, B-symptoms, and high IPI are poor prognostic markers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Jul;51(7):1159-60 [20497004.001]
  • (PMID = 20443676.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / beta 2-Microglobulin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone
  •  go-up   go-down


70. Kojima M, Shimizu K, Nishikawa M, Tamaki Y, Ito H, Tsukamoto N, Masawa N: Primary salivary gland lymphoma among Japanese: A clinicopathological study of 30 cases. Leuk Lymphoma; 2007 Sep;48(9):1793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary salivary gland lymphoma among Japanese: A clinicopathological study of 30 cases.
  • To clarify the clinicopathological findings of primary salivary gland lymphoma as defined by the World Health Organization (WHO) classification, 30 Japanese patients with this disease were studied.
  • Twenty-four (80%) cases demonstrated Stage IE, whereas only six (20%) had Stage IIE-1.
  • Histologically, 15 cases were mucosa-associated lymphoid tissue (MALT) lymphoma, seven were follicular lymphoma (FL), and six were diffuse large B-cell lymphoma (DLBCL) + MALT lymphoma and only two were DLBCL without a MALT lymphoma component.
  • MALT lymphoma is the most frequent type of primary salivary gland lymphoma.
  • However, FL comprised 20% of primary salivary gland lymphoma.
  • The majority of the primary salivary gland DLBCL appear to arise from MALT type lymphoma.
  • When appropriate therapy for histologic subtype is used, outcome of the primary salivary gland B-cell lymphoma appears excellent whether histologically indolent or aggressive.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786716.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Mansour MR: Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma. Expert Rev Hematol; 2009 Apr;2(2):133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma.
  • Mutations of the Ras family are one of the most common somatic events found in all human cancers, although they are relatively rare in T-cell acute lymphoblastic leukemia (T-ALL).
  • In the article being evaluated, the authors demonstrate that primary mice expressing oncogenic Kras have a block in T-cell differentiation at the double-negative 1 stage.
  • Cell lines established from some of the mice demonstrated sensitivity to γ-secretase inhibition, suggesting that even when NOTCH-1 mutations occur as secondary collaborating events, tumors retain a dependency on this pathway that might be exploitable clinically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2008 Oct 15;112(8):3373-82 [18663146.001]
  • (PMID = 21083447.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R: Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol; 2009 Jul;84(7):414-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
  • (1) study the incidence and clinical relevance of WHO grade 3/4 LON in a uniform group of patients with diffuse large B-cell lymphoma (DLBCL) in complete remission following curative rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) chemotherapy;.
  • Results of Fischer's exact test revealed that age, stage, LDH level, ECOG, marrow involvement, and hematologic parameters did not predict for LON development.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neutropenia / chemically induced

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415727.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


73. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol; 2008 Jun 1;26(16):2717-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
  • PURPOSE: To assess the clinical outcome and the influence of biomarkers associated with apoptosis inhibition (Bcl-2), tumor proliferation (MIB-1), and cellular differentiation on the outcome with dose-adjusted (DA) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) plus rituximab (R) infusional therapy in diffuse large B-cell lymphoma (DLBCL) with analysis of germinal center B-cell (GCB) and post-GCB subtypes by immunohistochemistry.
  • PATIENTS AND METHODS: Phase II study of 72 patients with untreated de novo DLBCL who were at least 18 years of age and stage II or higher.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / classification. Germinal Center / drug effects. Lymphoma, Large B-Cell, Diffuse / drug therapy


74. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer; 2008 Aug 15;113(4):791-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
  • BACKGROUND: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin's lymphoma.
  • RESULTS: Of the 87,166 patients diagnosed with non-Hodgkin's lymphoma during the 13-year period between 1992 and 2004, 2459 (2.8%) had confirmed MCL.
  • Late-stage (III-IV) MCL was diagnosed in 74.6% of patients.
  • Most patients were diagnosed with late-stage MCL, and there also were considerable geographic variations observed in incidence rate.
  • [MeSH-major] Lymphoma, Mantle-Cell / epidemiology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 American Cancer Society
  • (PMID = 18615506.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R01-HS016743
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


75. Magné N, Foa C, Castadot P, Otto J, Birtwisle-Peyrottes I, Thyss A: [Guillain-Barré syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature]. Rev Med Brux; 2005 Mar-Apr;26(2):108-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Guillain-Barré syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature].
  • [Transliterated title] Syndrome de Guillain-Barré et lymphome non-hodgkinien. A propos d'une observation et revue de la littérature.
  • Patients with lymphoma frequently develop neurologic abnormalities mainly due to nervous system infiltration but also direct drug toxicity.
  • Moreover Guillain-Barré syndrome (GBS) remains a possible neuropathy, rarely described in non-Hodgkin's lymphoma.
  • We describe a case of GBS in a patient with non-Hodgkin's high grade lymphoma.
  • A 74-year old man with a newly diagnosed stage I high-grade lymphoma (precursor B-cell Burkitt like type according to the R.E.A.L.
  • The low number of cases described in the international literature doesn't permit to understand the association of this neurologic disease with non-Hodgkin's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / complications. Guillain-Barre Syndrome / complications


76. Harrington CR, Guillén DR, Pandya AG: Evaluation of new tumors in the setting of stage I/IIA mycosis fungoides. Clin Lymphoma Myeloma; 2007 Jul;7(7):480-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of new tumors in the setting of stage I/IIA mycosis fungoides.
  • Although mycosis fungoides is usually a slowly progressive indolent lymphoma, new cutaneous tumors might signal an aggressive phase of the disease.
  • These tumors represented the following: mycosis fungoides without transformation, large-cell transformation of mycosis fungoides, lymphomatoid papulosis-associated CD30(+) lymphoproliferative disorder arising in a patient with mycosis fungoides, and a primary cutaneous CD30(+) lymphoproliferative disorder arising in a patient with mycosis fungoides.

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875239.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


77. Huang HQ, Peng YL, Cai QQ, Lin XB, Li YH, Xia ZJ, Lin TY, Sun XF, Zhang L, Xu GC, He YJ, Jiang WQ, Guan ZZ: [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens].
  • OBJECTIVE: To analyse the effectiveness and toxicity of combined chemotherapy regimen containing pirarubicin (THP) in the treatment of non-Hodgkin's lymphoma (NHL).
  • B-cell and T/NK cell NHL accounted for 68.4% and 23.2% respectively with 56.9% of diffuse large B cell lymphoma and 12.5% of peripheral T cell lymphoma.
  • 92.6% of the patients were ECOG < 1, 63.2% in stage I + II, 84.7% with IPI score 0 - 2 and 25% with B symptoms, 93.9% (368/392) of the patients received CTOP (containing THP) regimen chemotherapy and among them 28.5% (112/392) plus involved field radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Lymphoma, Non-Hodgkin / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532963.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


78. Karsai S, Hou JS, Telang G, Kantor GR, Nowell PC, Vonderheid EC: Sézary syndrome coexisting with B-cell chronic lymphocytic leukemia: case report and review of the literature. Dermatology; 2008;216(1):68-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sézary syndrome coexisting with B-cell chronic lymphocytic leukemia: case report and review of the literature.
  • INTRODUCTION: The simultaneous presentation of chronic B-cell lymphocytic leukemia (B-CLL) and cutaneous T-cell lymphoma (CTCL) is extremely rare.
  • DISCUSSION: We speculate that the coexistence of B-CLL and CTCL is the result of an initiating genetic or epigenetic defect at the level of the common lymphoid stem cell that predisposes both B-cell and T-cell lineages to additional oncogenic changes at a more advanced stage of differentiation.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Sezary Syndrome / complications. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD / analysis. B-Lymphocytes / metabolism. Fatal Outcome. Female. Humans. Male. Middle Aged. Receptors, Antigen, T-Cell, alpha-beta / analysis. Skin / pathology. T-Lymphocytes / metabolism


79. Pott C, Schrader C, Brüggemann M, Ritgen M, Harder L, Raff T, Tiemann M, Dreger P, Kneba M: Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease. Eur J Haematol; 2005 Apr;74(4):353-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
  • OBJECTIVES: Classical mantle cell lymphoma (MCL) and its blastoid variant (MCL-BV) are characterized by an extremely poor prognosis.
  • We present a case of a 41-year-old male with a 12 yr history of MCL stage I to show, that very late relapses in MCL are possible and may present as a transformation into an aggressive blastoid variant and to illustrate the value of quantitative minimal residual disease (MRD) monitoring for treatment guidance.
  • Therefore, treatment was early intensified by myeloablative radio-chemotherapy and allogeneic peripheral stem cell transplantation from an unrelated HLA-identical donor.
  • CONCLUSION: This report presents a rare case of long-term survivor of MCL with a progression of the original MCL cell clone to MCL-BV and demonstrates the clinical value of quantitative MRD assessment for optimized therapeutic management.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Base Sequence. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 14 / genetics. DNA, Neoplasm / genetics. Fatal Outcome. Genes, Immunoglobulin. Humans. Male. Peripheral Blood Stem Cell Transplantation. Time Factors. Translocation, Genetic

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Blackwell Munksgaard.
  • (PMID = 15777349.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


80. Dreyling M, Hoster E, Bea S, Hartmann E, Horn H, Hutter G, Salaverria I, Pott C, Trneny M, Le Gouill S, Cortelazzo S, Szymczyk M, Jurczak W, Shpilberg O, Ribrag V, Hermine O, European MCL Network: Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk Lymphoma; 2010 Sep;51(9):1612-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
  • Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in virtually all cases.
  • Advanced stage disease is usually apparent already at first clinical manifestation; thus, conventional chemotherapy is only palliative, and the median duration of remissions is only 1-2 years.
  • Emerging strategies including proteasome inhibitors, immune modulatory drugs (IMiDs), mTOR inhibitors, and others are based on the dysregulated control of cell cycle machinery and impaired apoptotic pathways.
  • In 2000 the European MCL Network ( http://www.european-mcl.net ) was founded, consisting of 15 national lymphoma study groups supplemented by experts in histopathology and molecular genetics.
  • In detail, in prospective randomized studies, the addition of a B-lymphocyte specific antibody doubled the median progression-free survival from 14 to 28 months, and a dose-intensified consolidation with high-dose radiochemotherapy and subsequent autologous stem cell transplant resulted in superior response duration (3.7 vs. 1.6 years) and even improved overall survival in a recent analysis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Mantle-Cell / etiology. Lymphoma, Mantle-Cell / therapy. Stem Cell Transplantation


81. Su ZY, Zhang DS, Zhu MQ, Shi YX, Jiang WQ: [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases]. Ai Zheng; 2007 Aug;26(8):919-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases].
  • BACKGROUND & OBJECTIVE: Primary paranasal sinus lymphoma (PPSL) is a rare presentation of extranodal non-Hodgkin's lymphoma with a natural history distinct from other lymphomas.
  • All patients were at stage I-II (Ann Arbor system).
  • Of the 14 patients, 12 had B-cell PPSL, 1 had T-cell PPSL, and 1 had unclassified PPSL.
  • The most common type was diffuse large B-cell PPSL (6 cases, 42.9%).
  • CONCLUSIONS: PPSL is an uncommon presentation of lymphoma characterized by bulky local disease.
  • Diffuse large B-cell lymphoma is the most common histologic type and the maxillary sinus is the most common original site of PPSL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / surgery. Maxillary Sinus / surgery. Middle Aged. Neoplasm Staging. Paranasal Sinuses / pathology. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697560.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


82. Marcus R, Hagenbeek A: The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl; 2007 Jan;(67):5-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic use of rituximab in non-Hodgkin's lymphoma.
  • The non-Hodgkin's lymphomas (NHLs) comprise a heterogeneous collection of lymphoproliferative malignancies, which are most common in people aged over 55 years.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for approximately 30% of all new patients.
  • Follicular lymphoma (FL) is the second most common NHL sub-type, and accounts for a further 22% of cases.
  • Over the last five years, the introduction of monoclonal antibodies, and specifically the anti-CD20 monoclonal antibody, rituximab, has radically changed treatment of B-cell NHL.
  • Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody which binds to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes.
  • This antigen is expressed on over 95% of all B cell NHLs, and on normal B cells, but not on haematopoietic stem cells, normal or malignant plasma cells.
  • The Fc domain of rituximab recruits immune effector functions to mediate B cell lysis.
  • It is also possible that the binding of rituximab to the CD20 antigen on the cell surface may directly induce apoptosis.
  • For patients with both follicular and diffuse large B-cell NHL, several large scale prospective randomised trials have demonstrated prolongation of remission when rituximab is incorporated into first line treatment, and, in follicular lymphoma, as a component of salvage therapy.
  • As a result of these studies, current European indications for rituximab include: the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with cyclophosphamide, vincristine and prednisone (CVP) chemotherapy; as maintenance therapy in patients with relapsed follicular lymphoma responding to induction therapy with chemotherapy or immuno-chemotherapy; the treatment of patients with diffuse large B cell NHL in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206982.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 39
  •  go-up   go-down


83. Cogliatti SB, Bertoni F, Zimmermann DR, Henz S, Diss TC, Ghielmini M, Schmid U: IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. J Pathol; 2005 Jul;206(3):320-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome.
  • Mantle cell lymphoma (MCL) is associated with a very unfavourable clinical course.
  • This is particularly true for mantle cell lymphoma of the blastoid subtype (MCL-b).
  • Thirteen of 21 cases of MCL-b revealed a homology rate of > or = 99% compared to IgV H germ-line sequences in the databases and were scored as non-mutated.
  • In MCL-b the mutation frequency was usually low and the mutation pattern was only rarely antigen-selected, in contrast to a control group of 11 cases with morphologically almost identical, but phenotypically and genotypically clearly distinguishable, diffuse large B cell lymphoma, derived, most likely, from germinal centre B cells.
  • However, mutated MCL-b tended to present more frequently at an earlier stage and without bone marrow involvement and to show lower rates of relapse and death, resulting in a more favourable clinical outcome.
  • [MeSH-major] Genes, Immunoglobulin / genetics. Lymphoma, Mantle-Cell / genetics

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 15887292.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


84. Dargent JL, Lespagnard L, Feoli F, Debusscher L, Greuse M, Bron D: De novo CD5-positive diffuse large B-cell lymphoma of the skin arising in chronic limb lymphedema. Leuk Lymphoma; 2005 May;46(5):775-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo CD5-positive diffuse large B-cell lymphoma of the skin arising in chronic limb lymphedema.
  • We report the case of a 79-year-old woman with a longstanding lymphedema of the right arm who developed a skin lymphoma involving the right wrist area.
  • No expression of anaplastic large cell lymphoma kinase (ALK), CD10, CD23, CD30, CD43, bcl-6, cyclin D1, p53 or p16INK4a could be seen.
  • The tumor was classified as stage IE and was first cured by complete surgical excision.
  • This study further illustrates that lymphoma of the skin may complicate chronic limb lymphedema.
  • Like most of the previously reported cases, this neoplasm belonged to the category of diffuse large B-cell lymphoma.
  • [MeSH-major] Antigens, CD5 / biosynthesis. Lymphedema / complications. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Skin Neoplasms / complications


85. Wang T, Liu YH, Zheng HY, Sun QN, Jin HZ, Li F, Fang K, Yan Y: [Hypopigmented mycosis fungoides in children: a clinicopathological study of 6 cases]. Zhonghua Yi Xue Za Zhi; 2010 Dec 14;90(46):3287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunohistochemical staining revealed a pattern of T lymphoma and a predominance of CD8+ T cell.
  • All patients were of T2N0M0/IB except for one at the stage of T1N0M0/IA.
  • The non-treated patient progressed gradually.
  • The prognosis of early-stage treatment is satisfactory.
  • NB-UVB alone or plus alpha interferon achieves a clinical CR in most early-stage patients.
  • [MeSH-major] Hypopigmentation / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Mycosis Fungoides / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223789.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Miyoshi N, Tanaka H, Ito T, Katayama Y, Niimi H, Hyodo H, Kimura A: Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase. Int J Hematol; 2005 Nov;82(4):333-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment also maintained the patient in good condition for approximately 3 months, even though the number of blast cells, serum calcium level, serum PTHrP level, and PTHrP mRNA level increased at the terminal stage.


87. Huang ML, Chen CC, Chang LC: Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer. Int J Colorectal Dis; 2009 Nov;24(11):1281-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer.
  • METHODS: The gene expressions of HMGI-C and HMGI(Y) in 31 paired samples of colorectal tumor and corresponding non-tumor were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR).
  • RESULTS: The expression of HMGI(Y) in a colorectal cancer tumor was associated with Dukes staging (p = 0.044), while, in non-tumor, the expression of this gene was significant with metastasis (p = 0.003).
  • Patients with Dukes stage A and B present high HMGI(Y) expression in non-tumor of colorectal cancer (p = 0.006).
  • However, patients with Dukes stage C and D present high HMGI-C expression in colorectal tumor (p = 0.023).
  • In the non-metastasis group, HMGI(Y) was highly expressed in non-tumor of colorectal cancer.
  • However, in the metastasis group, there was no significant difference between tumor and non-tumor tissues in both HMGI-C and HMGI(Y) gene expressions.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Colorectal Dis. 2010 May;25(5):661 [19921219.001]
  • [Cites] Langenbecks Arch Surg. 2004 Jun;389(3):193-7 [15107999.001]
  • [Cites] Mol Cancer Res. 2008 May;6(5):743-50 [18505920.001]
  • [Cites] Adv Anat Pathol. 1999 Sep;6(5):237-46 [10472377.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):37-43 [9212729.001]
  • [Cites] Oncogene. 1998 Jul 23;17(3):377-85 [9690519.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2007-14 [15041719.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3190-8 [12082634.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):25062-70 [9312114.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):376-80 [10404089.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1169-74 [10096541.001]
  • [Cites] Hum Genet. 1997 Jan;99(1):103-5 [9003504.001]
  • [Cites] Am J Pathol. 1996 Sep;149(3):775-9 [8780382.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1844-50 [19223528.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6622-30 [16061642.001]
  • [Cites] Eur J Biochem. 1991 May 23;198(1):211-6 [2040281.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):875-86 [17914116.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1996;54:35-100 [8768072.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1406-10 [12778070.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2008-13 [17917968.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4355-60 [7876198.001]
  • [Cites] Nucleic Acids Res. 1993 Sep 11;21(18):4259-67 [8414980.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6132-41 [11593421.001]
  • [Cites] Anal Biochem. 1986 Aug 15;157(1):53-62 [3464222.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1896-901 [8620511.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(15):1944-8 [11000575.001]
  • [Cites] Environ Health Perspect. 2000 Oct;108 Suppl 5:803-9 [11035986.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2024-9 [15026339.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5310-21 [9311991.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):573-8 [8761372.001]
  • [Cites] Pathol Res Pract. 2003;199(10):641-6 [14666966.001]
  • [Cites] Mol Cell Biol. 1992 Sep;12(9):3919-29 [1508193.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4193-8 [9751634.001]
  • (PMID = 19609535.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HMGA2 Protein; 124544-67-8 / HMGA1a Protein
  •  go-up   go-down


88. Koumarianou AA, Xiros N, Papageorgiou E, Pectasides D, Economopoulos T: Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades. Anticancer Res; 2007 Mar-Apr;27(2):1191-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
  • The prognostic factors, treatments and outcomes of 55 young adults (16-23 years old) with Hodgkin lymphoma (HL) treated in the Second Department of Internal Medicine Propaedeutic, Medical Oncology Unit, Athens University, over the past 25 years, are reviewed.
  • Additionally, the patients were retrospectively divided according to risk factors (abnormal erythrocyte sedimentation rate (ESR), bulky mediastinal disease, > 3 involved nodes and extranodal involvement) into low [stage I/II; five patients (9%)], intermediate [stage III with adverse prognostic factors; 18 patients (33%)] and high risk categories [stages IIB bulky and III/IV; 32 patients (58%)].
  • Current controversial issues surrounding this disease, including the role of radiotherapy, positron emission tomography (PET), bone marrow biopsy and stem cell transplantation are discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy


89. Baris S, Celkan T, Batar B, Guven M, Ozdil M, Ozkan A, Apak H, Yildiz I: Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma. Pediatr Hematol Oncol; 2009 Sep;26(6):467-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma.
  • OBJECTIVES: The authors evaluated the possible effect of DNA repair genes, XPD (Xeroderma pigmentosum group D) codon (312 and 751) and XRCC1 (X-ray repair cross-complementing group 1) codon (194 and 399) SNPs (single-nucleotide polymorphisms) on the risk of childhood B-cell lymphoma.
  • RESULTS: The authors observed no association between variation in the XPD codon Asp312Asn, Lys751Gln, and XRCC1 codon Arg399Gln polymorphisms and B-cell lymphoma for any parameter.
  • The frequency of XRCC1 194Arg/Trp genotype in B-cell lymphoma was significantly lower than that in controls (p = .005).
  • No significant relationship was found between genotypes and stage, lactate dehydrogenase, or bone marrow involvement.
  • CONCLUSIONS: XRCC1 194Trp allele may be associated with a protective effect against development of childhood B-cell lymphoma.
  • [MeSH-major] DNA Repair / genetics. DNA-Binding Proteins / genetics. Lymphoma, B-Cell / genetics. Polymorphism, Single Nucleotide / genetics. Xeroderma Pigmentosum Group D Protein / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19657998.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein
  •  go-up   go-down


90. Kim WY, Jeon YK, Kim TM, Kim JE, Kim YA, Lee SH, Kim DW, Heo DS, Kim CW: Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol; 2009 Oct;20(10):1688-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma.
  • BACKGROUND: Extranodal natural killer/T-cell lymphoma (NKTCL) is a clinically heterogeneous disease with a poor prognosis, requiring risk-stratified management in affected patients.
  • Recently, tumor microenvironment including regulatory T cells (Tregs) has been implicated as a prognostic marker in certain types of lymphoma.
  • The decreased number of Tregs (<50/0.40 mm(2)) was more common in patients with poor performance status or in those presented in non-upper aerodigestive tract.
  • However, the level of Tregs was not associated with other prognostic factors, including stage, lactate dehydrogenase level, International Prognostic Index, and NKTCL Prognostic Index.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542249.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


91. Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group: Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer; 2006 Sep 1;107(5):1014-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
  • BACKGROUND: In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades.
  • METHODS: The German Low-Grade Lymphoma Study Group performed a randomized trial comparing combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) chemotherapy with combined mitoxantrone, chlorambucil, and prednisone (MCP) chemotherapy as first-line therapy for patients with advanced-stage FL or MCL.
  • RESULTS: Three hundred sixty-three patients with advanced-stage FL (n = 277 patients) or MCL (n = 86 patients) entered the trial and were evaluable fully.
  • The proportion of patients who successfully underwent peripheral blood stem cell collection was significantly lower after MCP (44% vs. 93% after CHOP; P = .0003).
  • Particularly in younger, high-risk patients who are candidates for autologous stem cell transplantation, CHOP should be preferred over MCP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878325.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol; MCP protocol
  •  go-up   go-down


92. Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT: Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A; 2005 Apr 26;102(17):6068-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia.
  • We have created a stable transgenic rag2-EGFP-mMyc zebrafish line that develops GFP-labeled T cell acute lymphoblastic leukemia (T-ALL), allowing visualization of the onset and spread of this disease.
  • These T cell leukemias are clonally aneuploid, can be transplanted into irradiated recipient fish, and express the zebrafish orthologues of the human T-ALL oncogenes tal1/scl and lmo2, thus providing an animal model for the most prevalent molecular subgroup of human T-ALL.
  • Transgenic progeny from one of these lines can be induced to develop T-ALL by injecting Cre RNA into one-cell-stage embryos, demonstrating the utility of the Cre/lox system in the zebrafish and providing an essential step in preparing this model for chemical and genetic screens designed to identify modifiers of Myc-induced T-ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • The Lens. Cited by Patents in .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Development. 1996 Dec;123:1-36 [9007226.001]
  • [Cites] Immunogenetics. 2000 Sep;51(11):915-23 [11003385.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Dec;29(4):371-7 [11066085.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):12965-9 [11087852.001]
  • [Cites] Genesis. 2001 Apr;29(4):156-62 [11309848.001]
  • [Cites] Nucleic Acids Res. 2001 Jun 1;29(11):E53-3 [11376165.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1495-504 [11587205.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):1481-91 [11591315.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7447-52 [11704876.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):135-40 [12006978.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Blood. 2002 Aug 1;100(3):991-7 [12130513.001]
  • [Cites] Mech Dev. 2002 Sep;117(1-2):243-8 [12204264.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):176-81 [12619103.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 15;31(8):e44 [12682379.001]
  • [Cites] Leukemia. 2003 May;17(5):887-93 [12750702.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):595-9 [15097998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7369-74 [15123839.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] N Engl J Med. 1987 Jan 8;316(2):79-84 [3537802.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1035-48 [2598259.001]
  • [Cites] Science. 1990 Jun 22;248(4962):1517-23 [2360047.001]
  • [Cites] Leukemia. 1991 Oct;5(10):839-40 [1961018.001]
  • [Cites] Science. 1994 Jul 1;265(5168):103-6 [8016642.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3105-12 [7949183.001]
  • [Cites] Blood. 1995 May 1;85(9):2321-30 [7727766.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):407-12 [15630097.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3278-85 [15618471.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3497-502 [10737801.001]
  • (PMID = 15827121.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] PIR/ AF398514
  • [Grant] United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / CA-06516; United States / NCI NIH HHS / CA / CA-68484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / Genetic Markers; 0 / Nuclear Proteins; 0 / RAG2 protein, human; 0 / Rag2 protein, mouse; 0 / V(D)J recombination activating protein 2; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 149137-54-2 / Lox protein, mouse; EC 1.4.3.13 / Protein-Lysine 6-Oxidase; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC1087915
  •  go-up   go-down


93. Xue LY, Lü N, Li AD, Zou SM, Lin DM, He ZG, Xie YQ, Liu XY: [A clinicopathological analysis of gastric lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2005 Jun;34(6):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinicopathological analysis of gastric lymphoma].
  • OBJECTIVE: To discuss the clinicopathological features and prognostic factors of gastric lymphoma.
  • METHODS: 83 gastric lymphoma cases were analyzed retrospectively in accordance to the criteria of the new World Health Organization classification for neoplastic diseases of the hematopoietic and lymphoid tissues.
  • According to the new World Health Organization classification for neoplastic diseases of the hematopoietic and lymphoid tissues, 57 cases were extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type (MALT lymphoma), 23 were diffuse large B cell lymphoma accompanying MALT lymphoma, 2 were diffuse large B cell lymphoma and 1 was follicular lymphoma.
  • Of all the cases, 31 were stage I E, 38 stage II E, 8 stage III E and 6 stage IV by the Ann Arbor staging system (1972).
  • The 5-year and 10-year survival rates of MALT lymphoma were 77.4% and 72.3%, the 5-year and 10-year survival rates of diffuse large B cell lymphoma accompanying MALT lymphoma were 81.8% and 68.2%, the 5-year survival rate of diffuse large B cell lymphoma was 50.0%.
  • CONCLUSIONS: There are no specific symptoms in gastric lymphoma patients.
  • Extranodal marginal zone lymphoma of MALT-type is the main histopathological type of gastric lymphoma, often accompanied by multiple mucosa involvement and also often accompanied by a history of chronic gastric disease.
  • Survival rate has a significant correlation with lymph node involvement and clinical stage.
  • [MeSH-major] Gastrectomy. Lymphoma / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate